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ABSTRACT  
Background 
The trend of postponed reproduction to late in life has increased demand for fertility 
treatment. The current program of subsidized ART-treatment in Sweden is 
thoroughly debated and critiqued. The Swedish National Council on Medical Ethics 
has highlighted the ethical shortcomings of the current system and called for a 
program change. This thesis expands on the proposal and introduces a medical 
screening program as a qualification aid for subsidized fertility. 
Method and Data 
To compare the current Strict Age Limited Program with the Medical Screening 
Program a cost-effectiveness analysis is conducted. The results are presented as 
incremental cost-effectiveness ratios (ICER). Data is collected from the RMC clinic 
and supplemented with national data (National Quality Register for ART-treatment) 
in the age groups where RMC data is lacking.  
Results  
Introducing the Medical Screening Program with the current Strict Age Limited 
Program generated a cost increase of SEK 2 244 (SEK 20 058) and a rise in the 
number of live births by 62 (48) for the RMC (Q-IVF) data set. Thereby the analysis 
resulted in an ICER of SEK 36 (SEK 429). The ICER is thus fairly unaffected while 
the number of live births rises significantly. A sensitivity analysis shows expected 
results and the overall effect seems negligible. It is also noteworthy that approxi-
mately three fourths of the societal costs of publically funded ART-treatment fall on 
the health care region, while the rest is divided between the patients and their 
employers.  
Conclusion 
Increased availability of publically funded ART-treatment may induce counter-
productive behavior but the trend of increased demand is most likely related to 
shifting social norms. It is essential for western countries to promote fertility rate, due 
to the economic implications of an aging population, and the Medical Screening 
Program has potential to do so.  
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1. INTRODUCTION 
Declining fertility rates have been observed for several decades in most industrialized 
countries (McDonalds, 2006). During the last century the average number of children 
born per woman in Sweden has decreased from approximately 4 to 1.9 children per 
woman. For the population to reproduce itself, without the help of immigration, every 
woman needs to give birth to an average of 2.1 children during her lifetime, usually 
referred to as the replacement rate of fertility (Statistics Sweden, 2012:I). If the 
downward fertility trend continues, it will cause an ageing of the average population, 
which will have negative spillover effects on the pension system. We can already see 
changes in the population pyramid compared to the early 20th century, and prognosis 
predicts that the population pyramid might even turn upside-down in the future 
(Statistics Sweden, 2012:II). This demographic trend indicates negative economic 
consequences for countries with low levels of reproduction and hence calls for actions 
to increase, or even stabilize, fertility rates (Rainer et al, 2011).  
 
One way for the welfare state to influence the levels of reproduction is through 
strategies and regulations regarding assisted reproduction technology (ART) 
treatments, such as IVF or ICSI. Involuntary childlessness is an increasing problem, 
especially in the western world, primarily caused by the societal trend to have 
children at a higher age. The average age of both men and women at time of birth of 
their firstborn has increased. In 1970 the average age of a woman having her first 
child was 24 years old, while the man was 27 years old. By 2011 the same ages had 
risen to 28.9 for women and 31.5 for men (Statistics Sweden, 2012:I). 
 
Still, most people take reproduction for granted. We often view reproduction as the 
natural way of life even though it might not be as unproblematic as one may think. In 
Sweden approximately 15% of all couples in reproductive ages experience some 
fertility problems (Barnlängtan, 2013; McQuillan, 2012). Involuntary childlessness 
occurs when a couple has tried to get pregnant in the natural way for at least one year 
without succeeding, and are thus in need of medical assistance to reproduce (WHO, 
2013). In 1997 involuntary childlessness, or more accurately infertility, was classified 
as a disease by the World Health Organization, WHO (WHO, 2011). 
 
Evidence presented by de la Rochebrochard (2001) suggests that in the ages 35-39 
and 40-44 respectively, it is almost 20% and 50% less likely for a woman to naturally 
conceive compared to 25-29 year-old women.  This problem increases as reproduction 
is put forth to later in life. According to Swedish data, every fourth woman between 
34 and 40 years old have used some kind of fertility aid (Statistics Sweden, 2009), and 
approximately 3.3 percent of the annual births in Sweden are results of ART-
treatment.   
 
This thesis aims to highlight the effect of age on fertility and evaluate the current 
subsidy program for ART-treatment. This leads us to the main question; Would it be 
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cost-effective to implement a medical screening system to determine eligibility for 
ART-treatment, for women aged 35-43, instead of retaining the current fixed age limit 
of <39? We aim to clarify the existing regulations of publically funded ART-
treatment in Sweden, and compare it with a proposed regulation change of a lower age 
limit of 35 years, accompanied with individual medical screening of women aged 35-
42. The different treatment programs will be studied through a cost-effectiveness 
analysis.  
 
The remainder of this thesis will be structured as follows; section 2 contains the 
outlines of the current ART-treatment program, its restrictions and critique as well as 
a proposed program change with which it will be compared throughout the thesis. 
Section 3 describes the methodological framework, motivates the choice of method 
and explains how it is applied. In section 4 presents the data sets used in the thesis and 
depicts what alterations have been made. In section 5 thorough descriptions of the 
cost calculation process is presented. Section 6 presents the results of the thesis, 
which are then discussed in section 7. Finally, section 8 presents the conclusions 
drawn.  
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2. BACKGROUND 
2.1. Current Swedish legislation 
Assisted reproduction in Sweden is primarily regulated by the Genetic Integrity Act 
(SFS 2006:351), in addition to guidelines from the National Board of Health and 
Welfare (NBHW) and international consensus (i.e. the EU directive 2004/23/EG and 
the UN convention on children’s rights) (SMER, 2013). Currently, fertility treatment 
is provided under the following restrictions. First, both heterosexual and lesbian 
couples are eligible for fertility treatment (SoU26, 2011/12). Meanwhile, couples 
where the woman is unable to carry a child, HBT couples (see the fourth restriction) 
and singles are not offered treatment.1 Secondly, both egg and sperm donation is 
legalized in Sweden. However they are not allowed simultaneously as the 
forthcoming child has the right to a biological tie to at least one of his/her parents. If 
donated sperm or eggs are used the couple receiving the donation has to undergo a 
suitability evaluation to ensure that the prospective child will grow up under favorable 
conditions. The evaluation takes medical, psychological and social circumstances into 
account. Couples who use their own gametes (eggs and sperm) in ART-treatment do 
not undergo any evaluation. Thirdly, donors cannot be anonymous but are usually 
unknown to the prospect parents. Information about the donor’s identity is kept in a 
database so that the child is able to find his or her biological heritage when reaching 
adulthood. However, the donor has no legal obligation to the child. Fourthly, 
surrogacy is not allowed in Sweden. Fifth and final, there is no legislated age limit to 
fertility treatment (SMER, 2013).  
 
2.1.1. Regional ART-treatment regulations 
Even though there is no legislated age restriction of ART-treatment in Sweden, the 
reality is somewhat different. Sweden’s democratic system relies on regional 
autonomy and is divided into independent county councils (SMER, 2013). Sweden 
has universal health care and each county council has the authority and obligation to 
make prioritizations and budgetary decisions. Therefore, and because there are 
scientific evidence of decreasing fertility with increasing age all county councils have 
endorsed age restrictions to publically funded ART-treatment. The age restrictions, 
however, vary between regions. The primary focus is female age in all county 
councils, as males stay fertile later in life, and the limits vary from 37-41 years for 
women and 54-56 years for men (SMER, 2013). For further details on age-restrictions, 
see appendix table 22. 
                                                        
1 It is nationally regulated that both heterosexual and lesbian couples are eligible for reproductive 
treatment. A decision in the Swedish Parliament in 2012 also suggested that single women should be 
allowed fertility treatment and that a commission should be put together to draw out a legislative 
proposal as soon as possible (SoU26, 2011/12). To this day no such proposal has been presented.  
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Most county councils have developed regional collaboration units in order to fully 
utilize the medical expertise in the area to provide its inhabitants with optimal health 
care. Fertility clinics are fairly scarce and there is often only one publically funded 
medical unit providing ART treatment per health care region. Consequently, these 
health care regions have unified restrictions regarding fertility treatment. As shown in 
table 1 there are multiple criteria that vary across regions, however this study will 
solely focus on the female age restriction.  
 
 
Table 1. Regional ART-treatment regulations 
 
 
South Southeast West Stockholm-
Gotland 
Uppsala-
Örebro 
North 
County 
Councils, 
included in 
Health Care 
Region 
Skåne, 
Blekinge, 
Kronoberg, 
South 
Halland 
Östergötland
, Jönköping, 
Kalmar 
Västra 
Götaland, 
North 
Halland 
Stockholm, 
Gotland 
Gävleborg, 
Dalarna, 
Uppsala län, 
Värmland, 
Örebro, 
Västmanland 
Norrbotten, 
Jämtland, 
Västerbotten, 
Västernorrland 
Experienced 
infertility to 
qualify for 
treatment 
Medical 
indication 
required 
> 2 years > 1 year 
> 1 year, 
unless 
documented 
reproduction 
challenges 
> 1 year > 1 year 
Maximum 
age, women 
< 39 25-38 (<39) < 39 < 40 < 40 < 37 
Maximum 
age, men 
< 55 25-55 (<55) < 55 < 56 < 55 < 55 
Existing 
children 
No mutual 
children, 
includes 
adoptees 
No mutual 
children, 
excludes 
adoptees 
No 
mutual 
children, 
includes 
adoptees 
No mutual 
children, 
includes 
adoptees 
No mutual 
children 
At least one of 
the parents is 
childless 
BMI, 
women 
< 30 < 30 < 35 < 35 <35 <30 
Source: Information retrieved from each regions official website, see separate reference list in references. 
 
2.1.2. Critique of the current strict age limit programs  
As Sweden has a publically funded universal health care system with a restricted 
budget, prioritizations are required. The Swedish health care system rules under the 
following statutory ethical prioritization preferences: 
 
- The principle of human dignity 
All people are of equal value and have equal rights regardless of personal 
characteristics and societal functions  
- The need and solidarity principle 
Resources should primarily be allocated to areas where the need is greater 
- The cost-effectiveness principle 
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Choices between various activities or actions should seek a reasonable 
relationship between cost and effect, in terms of health and quality of life. 
 
It is incompatible with the ethical principles to neglect a person’s medical need due to 
characteristic such as age. However, in particular cases, circumstances that are 
limiting the benefits of a medical intervention can be taken into reconsideration (RiR 
2004:9). For example, if age is an obvious reason for negative outcomes from a 
specific treatment, age-regulations are entitled. However, since fertility is individual 
and not strictly age-related, a medical screening system could improve the agreement 
with the ethical principles compared to the current age-restricted system.  
 
The second paragraph of the Health and Health Care Law (SFS 2010:243, §2) states 
that the health care’s objective is to provide good health and health care on equal 
terms for the whole population. The legislation indicates that health care should be 
distributed in respect of all people’s equal worth and the individuals’ dignity. Those in 
greater need of health care should be prioritized. Therefore a system of four 
prioritization categories has been developed and every possible condition is classified 
thereafter. Prioritization group I, II and III was included in the universal health care 
system while the conditions in class IV were viewed as the individual’s own 
obligation and treatment of which was thus not subsidized. ART-treatments are 
classified in prioritization group III and thereby included in the universal health care 
benefits (SMER, 2013). This in turn means that ART-treatment should be allocated 
according to the recommendations by the Health and Health Care Law, and thus be 
supplied on equal terms for the whole population. A critique of today’s system is thus 
that it does not follow the equality restriction if a woman of 39 is allowed publically 
funded fertilization treatment in one county but is referred to out-of-pocket treatment 
in another. It is noteworthy that it is the regional regulations that establishes what 
treatment a couple can seek and it is thus not possible for a discriminated couple to 
seek subsidized ART-treatment elsewhere.  
 
Furthermore, in a survey directed towards the county councils regarding fertility 
treatment, 9 out of 21 county councils found the situation so challenging that they 
called for a nationwide harmonization of the ART-treatment restrictions. The primary 
motivation was that an equalization of health care benefits patients (SKL 2012; 
SMER, 2013). The current inequality argument is also the strongest argument of the 
interest organizations for reproductively challenged individuals in Sweden called 
Barnlängtan (Child Longing). They argue that the age limits are randomly set across 
the nation and lack scientific ground. As a consequence of the varied treatment and 
availability across the nation, multiple cases of discrimination and indignity charges 
have risen (Barnlängtan, 2013). 
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2.2. ART-treatment in Skåne Regional Council 
As this study will focus on the situation in Skåne, the current regulations for 
subsidized treatment in the county council of Skåne, (Skåne Regional Council, SRC), 
is presented in more detail in this section. All information about the treatment 
procedures were retrieved from the Reproductive Medicine Center’s (RMC) website 
(RMC, 2013) and by direct communication with medical professionals at the clinic2.  
 
As previously stated the age limits to qualify for ART-treatment in SRC is for the 
woman to not have turned 39 and for the man to not have turned 55. In addition, the 
couple (heterosexual or lesbian) cannot have any mutual children and the treated 
woman has to have a BMI below 30 (see table 1). To further limit the treatment 
utilization, the number of fully reimbursed treatment cycles per couple is limited. The 
limited number of publically funded treatment cycles is related to an increasing 
incremental cost, but also to an increasing cost per cycle with each attempt. For each 
ART-treatment cycles, the probability for the treatment to be successful decreases 
(Griffiths et al., 2010).   
 
SRC use a point system, where each couple entering RMC is assigned a pool of six 
points. Each therapy is worth a fixed amount of points and the couple’s points can 
then be freely allocated between therapies. For example, one hormone stimulation, 
including egg aspiration, resulting in an embryo transfer (ET) is worth 2 points. Thus 
each couple is provided with a maximum of three full treatment cycles free of charge. 
If the ET does not result in a live birth, and more than one egg was retrieved and 
fertilized in the first hormone stimulation cycle, these have been kept frozen and can 
be thawed and transferred into the uterus at a cost of 1 point (see figure 2 in 
appendix). If, at any point, the treatment results in a live birth all of the couple’s 
remaining points are exhausted. If the couple runs out of free points they can choose 
to proceed with treatment with out-of-pocket payment at a private clinic (RMC, 
2012:II).  
 
2.2.1. Treatment schedule 
To adequately comprehend the ART-treatments, a more detailed description of the 
medical practice is needed. Therefore this section present the RMC treatment 
schedule. All information presented here is retrieved from RMC (2012:I), unless 
otherwise stated.  
  
To start ART-treatment the couple is either remitted to RMC by a gynecologist or has 
filled out a private referral form online. During the first visit blood tests and sperm 
samples are given, as well as a full gynecological examination including ultrasound. 
When the test results comes back an individual treatment plan is drawn out and 
                                                        
2 Personal comunication with Aleksander Giwercman, Mona Bungum and Margareta Kitlinski 
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hormone ordinations are discussed between the couple and a physician. A nurse will 
then instruct the couple on how to dose the hormones, as exact compliance is essential 
for a successful treatment outcome. The first hormone injection is the actual starting 
point of the treatment.   
 
There are several steps in the hormone stimulation. Before the actual stimulation can 
start, a down-regulation of the female’s natural hormones is sometimes required. This 
makes it easier to control the active hormone treatment and thus to determine the 
exact time of egg aspiration. When the woman’s natural hormones are under control 
active hormone treatment is initiated. The hormone stimulation is individually 
adjusted and aims to get the ovarian follicles to grow. The follicles contain the 
oocytes that mature into eggs and in the natural menstrual cycle the follicle 
development culminates in ovulation. In a natural menstrual cycle only one egg 
matures, but to increase the chances of getting pregnant the hormone stimulation aims 
to produces multiple oocytes. Six days after the hormone stimulation is initiated, the 
hormone values are controlled through a blood sample. The blood tests tell the 
physician whether the stimulation is well adjusted or needs alteration. In three 
additional days a vaginal ultrasound is performed to examine whether the hormones 
have stimulated a desirable oocyte production.  
 
The hormone stimulation aims to optimize the egg aspiration. When most of the 
follicles have a diameter of approximately 18 millimeters and blood tests show an 
appropriate hormone level, it is time for the aspiration. This usually occurs 12 to 16 
days after the hormone stimulation is initiated, depending on treatment protocol. 
However, the exact time of egg aspiration cannot be determined until two to three 
days before the intervention due to the risk of insufficient follicles growth. Exactly 36 
hours prior to egg aspiration special hormone stimulation is injected to help the eggs 
mature. The egg aspiration is performed vaginally with the aid of an ultrasound. On 
average, eight eggs are collected per hormone stimulation cycle.  
  
Simultaneous to the egg aspiration the man gives a sperm sample. To maximize the 
result, the sample is refined in the lab by extracting the sperm with the highest quality 
before inseminated into the egg.  
 
Two to five hours after the eggs are retrieved they are ready for fertilization. There are 
two different techniques to fertilize eggs, the choice of which depends on the quality 
of the sperm.   
 In vitro fertilization (IVF): approximately 150,000 sperms are united with each 
egg. A single sperm will find its own way into the egg. 
 Intra-cytoplasmic sperm injection (ICSI): a single sperm is collected and 
injected straight into the egg. 
IVF is the technique used when the sperm quality is good while ICSI is used to treat 
sperm defects. As a precaution all retrieved eggs are inseminated.  
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After insemination, the eggs are put in a nutrient liquid and kept at 37 degrees. If the 
eggs have been fertilized it will split into two cells after 24 hours. The cells continue 
to multiply and eventually create an embryo. Medical experts at RMC estimate that 
60-70% of the eggs will develop into embryos3. 
 
Two to five days after the egg is inseminated, the embryo is developed enough to be 
transferred into the woman’s uterus. This is simply called an embryo transfer (ET). 
The perfect time for ET vary between couples and depend on the embryos’ 
development pace. In Sweden a single embryo is usually transferred at the time, 
according to recommendations by NBHW introduced in 2003 (Granberg, 2004). 
Single ETs reduces the chance of initial pregnancy but increases the odds for a 
confirmed pregnancy to result in a live birth. Multiple ETs increases the probability 
for multiple pregnancies, which causes significant health care risks for both the 
fetuses and the mother (Kjellberg et al., 2006). Multiple ETs are still performed in 
Sweden, but are an exception to the rule. (Ferraretti et al., 2012).  
 
Following the ET, hormone treatment continues to provide an optimal growth-
environment for the embryo. The treatment proceeds until pregnancy can be 
confirmed two weeks after ET. If the pregnancy test is negative, new treatment is 
scheduled as soon as possible if the couple wishes to try again. If the pregnancy test is 
positive an early ultrasound is performed after 6 weeks to ensure the health of both the 
fetus and the mother.  
 
2.3. Proposed regulatory changes  
Due to the objections of different age limitations across the country several 
propositions for change has been presented over the years. There are two main 
propositions relevant for consideration in this study.  
 
First, the Swedish National Council on Medical Ethics presented a report in January 
2013 on ethical aspects of assisted reproduction, including a discussion on the current 
age limits. The council found the current legislation insufficient in several aspects. 
Specifically the increased demand for ART-treatment and the change in public 
opinion were held as two main arguments for reconsideration. Moreover, the council 
found the current treatment supply to be suboptimal in relation to the medical 
development in the area. As no statutory age limits exist and because there are good 
medical prospects even for older women to become pregnant under the right 
circumstances, the Swedish National Council on Medical Ethics argues that general 
age limits are inappropriate, and unethical. Instead the best interest of the prospective 
child should be prioritized simultaneous with consideration of the woman’s medical 
prospects. Therefor the Swedish National Council on Medical Ethics recommends an 
abolition of the general age limit in the county councils in favor of individual 
                                                        
3 Personal communication with Margareta Kitlinski 
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assessment (SMER, 2013). 
  
Second, medical professionals at RMC in the Southern Health Care Region have 
alerted us to the potential deficiencies of the current strict age-limit program. In their 
professional opinion, a strict age limit is not necessarily the most efficient treatment 
allocation as ageing is individual. For example, it might not be the case that a 37-year-
old female has superior biological prerequisites to achieve a live birth compared to a 
41-year-old woman, on an individual level. In some cases it would be more efficient 
to allocate the medical resources towards the older woman. Therefore, RMC wishes to 
implement a medical screening system to determine who is eligible for treatment4. 
Apart from the medical differences in ageing, a further argument for RMC proposal is 
that Sweden’s universal health care system rules under the statutory ethical 
prioritization preferences previously listed. 
 
There are strong medical indications of severe and accelerating deterioration of the 
reproductive ability in women over the age of 35 (Piette et al., 1990). In contrast to 
the Swedish National Council on Medical Ethics, RMC professionals argue that 35 
would be a suitable age limit under which universal reproductive treatment should be 
supplied 5 . However, the biological ageing is individual and there are studies 
suggesting that some women are able to reproduce well over 39 (Suchartwatnachai et 
al., 2000; SBU, 2012; SMER, 2013). Couples who do not qualify for publically 
funded ART-treatment have the option of seeking care at private clinics, which is then 
funded out-of-pocket. However, it is very unusual that ART-treatments are offered to 
woman >42 in any clinic in Sweden.6 The proposal from RMC is to supply universal 
ART-treatment for women under 35 and to welcome women aged 35-42to undergo 
medical assessment in order to decide whether they are viable for further treatment.  
 
This study will henceforth focus on evaluating the RMC proposal, instead of the 
Swedish National Council on Medical Ethics proposal, and compare its cost-
effectiveness with today’s strictly age-limit program. The medical experts at RMC 
states that the ratio of women under 35 who would be proven not suited for further 
treatment after a medical screening is marginal, even though female reproductive 
qualities start to decline as early as at the age of 25 (Piette et al., 1990). The cost of 
pursuing the screening process for all ages, is assumed to be more costly, or at least 
equal the cost of supplying treatment for the women under 35 where it lacks effect.  
 
2.3.1. The medical screening process 
The RMC proposal includes a medical screening of women aged 35-42. However, 
even though using a medical screening process the couple still need to pass the 
                                                        
4 Personal communication with Aleksander Giwercman, Mona Bungum and Margareta Kitlinski 
5 Personal communication with Aleksander Giwercman and Margareta Kitlinski 
6 Personal communication with Aleksander Giwercman 
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original qualification criteria of BMI, mutual children and age restrictions. The couple 
will follow the previously described treatment schedule until egg aspiration, then 
satisfactory treatment response will be evaluated. 
 
The screening process was defined by medical expertise at RMC to consist of 
hormone stimulation where the resulting egg production constitutes the qualification 
criteria. The treshold for satisfactory treatment response is defined as retrieving at 
least four eggs at egg aspiration. Four eggs is assumed to be the cut off to make ET, 
the next treatment step, probable7. This is in line with the European consensus of a 
poor response to hormone stimulation treatment (Ferraretti et al., 2011). If less than 
four eggs has been retrieved after hormone therapy then the couple will not be 
approved for further ART treatment at a publically founded clinic.  
 
The proposed treatment regimen will hereafter be referred to as the Medical Screening 
Program (MS program in tables). 
 
2.4. Previous literature 
Previous economic evaluations of ART-treatment have held different perspectives, 
mainly due to the complexity in defining the target outcome. In general, health 
economic evaluations weigh a health intervention’s costs against its benefits in an 
attempt to evaluate whether it brings a positive net gain and thus is worth pursuing. It 
evaluates where and how to allocate limited budgets earmarked for health care to 
maximize health outcomes.  In order to compare the costs of a health intervention to 
its benefits in monetary or other comparable terms, the first step is to define what 
those costs and benefits are. There is a generally accepted methodology within the 
field of health economic evaluations to follow (Drummond et al., 2005; Evers et al., 
2005; Philips et al., 2004). However, evaluating ART-treatments aggravates the 
definitions. Primarily, the definition of the ART-treatments’ benefits is somewhat 
ambiguous. While the extent of most treatment outcomes can be measured in gained 
quality adjusted life years (QALYs), a successful ART-treatment creates a new life in 
addition to treating the infertility in the prospective parents.  
 
The purpose of the treatment is to help infertile couples to reproduce. But is it a 
pregnancy that we wish to attain, or a live birth? Most people argue that the medical 
goal with ART-treatment is a live birth (Garceau et al., 2002). However, a live birth 
means that a new person is brought to life and to determine the economic value or 
benefits of an additional human life is a complicated matter, to say the least (Simon, 
1975; Rice et al., 1967).  
 
                                                        
7 Personal correspondence with Aleksander Giwercman and Margareta  
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Previous economic evaluations have mainly defined the benefits of ART-treatment in 
three different ways. First, some have limited the benefits to a live birth and thus 
ignored what the creation of an additional person is worth in monetary terms 
(Suchartwatnachai et al., 1999; Hirshfeld-Cytron et al., 2012; Neumann et al., 1994; 
Wølner-Hanssen et al., 1998; Griffiths et al., 2010). Instead of monetary values, these 
studies concentrate on estimating the cost per live birth and leaving it to decision 
makers to evaluate whether or not the benefit of a live birth is worth the cost. Some 
even disregard the outcome of ART-treatment and simply estimate the cost per 
treatment cycle, however successful (Bouwermans, 2008), or present multiple cost-
estimates such as cost per cycle and per live birth (Van Voorish et al., 1998). 
Secondly, a number of studies have considered the economic interaction between the 
additional person and the state (Svensson et al., 2008; Connolly et al., 2008).  
Calculating the present value of both ART-treatment plus other governmental 
expenses that a person is accredited during a lifetime, such as schooling and health 
care, and the governmental income from taxation paid by an average individual during 
a lifetime. The net present value (NPV), the present value of governmental income 
minus governmental expenditures during an average lifetime, is calculated and 
considered as an investment bringing a return equivalent to the NPV. Third and final, 
some previous studies have chosen to consider what a child is worth to its infertile 
parents, who generally have spent years in agony prior to its birth. Here health effect 
of infertility, mental as well as physical, is estimated and the increased quality of life 
assumed to credit the child’s parents is considered (Granberg et al., 1995; Neumann et 
al., 1994; Ryan, 1998).  
 
Generally, economic evaluations aim to include a time perspective long enough for 
both costs and benefits to fully show. In this way the chosen time horizon will not 
affect the end result through missing data (Drummond, 2005). Considering that the 
benefit is a person, who contributes to the economy in production and consumption 
and who in turn may reproduces and thus start another production/consumption cycle, 
such time horizons are hard to fixate.  
 
This study will limit the benefit-side of the evaluation to a live birth, which is an 
approach used in most previous studies (Neumann et al, 1994; Wølner-Hanssen et al., 
1998; Griffiths et al., 2010). The argument for this is that the infertility, the initial 
diagnosis, is cured at childbirth. As curing the patient is the ultimate goal of any 
health care intervention we choose childbirth as our endpoint.  
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3. THEORY AND METHOD 
3.1. Methods of economic evaluation 
There are four main methodologies to consider when conducting an economic 
evaluation. Each methodology evaluates the costs of implementing a health care 
innovation; three of them also consider its health benefits. What diverges the 
methodologies is primarily the way they measure and value the benefit-side of the 
innovation (Drummond et al., 2005), see table 2, and are thus suited for different 
evaluations depending on the study-specific objective and data availability.  
 
In an attempt to justify our choice of methodology each of the four alternatives are 
presented below, including a declaration of its suitability to our material and study 
objective. This study evaluates the provision of publically founded ART-treatment, 
which, for compliance, will be referred to as the treatment in this section.  
 
Table 2. Characteristics of evaluation methods 
Type of study Measurement / 
valuation of costs in 
both alternatives 
Identification of health 
benefits 
Measurement / 
valuation of health 
benefits 
Cost analysis 
(CA) 
Monetary units None None 
Cost-
effectiveness 
analysis  
(CEA) 
Monetary units Single effect of interest, 
common to both alternatives, 
but achieved to different 
degrees 
Natural units 
(e.g. life-years gained, 
number of live births 
etc.) 
Cost-utility 
analysis  
(CUA) 
Monetary units Single or multiple effects, not 
necessarily common to both 
alternatives 
Healthy years (typically 
measured in quality-
adjusted life years) 
Cost-benefit 
analysis  
(CBA) 
Monetary units Single or multiple effects, not 
necessarily common to both 
alternatives 
Monetary units 
Source: Drummond et al. 2005  
 
The first economic evaluation method is the Cost Analysis (CA), which exclusively 
evaluates the cost-side of a treatment. The CA is only applicable when the compared 
treatment effects can be proven, or assumed, equivalent (Drummond et al., 2005). As 
it is assumed that a reallocation of fertility treatments would affect the outcome, CA 
was not an appropriate method for our analysis. The following methodologies, 
however, all include the evaluated treatment’s health benefits.  
 
The second evaluation method is the Cost-Effectiveness Analysis (CEA), which 
identifies and presents the most appropriate natural measure of the treatment’s 
benefits. Examples of such natural measures include the number of gained life years, 
deterred heart attacks or live births. A monetary value of the health benefits is 
disregarded, but the outcome of the treatment is considered beneficial and desirable. 
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A CEA requires that the evaluated treatments bring the same kind of health benefits, 
but allows for a varied extent (Drummond et al., 2005). In other words, there is a 
single treatment effect of interest mutual to both treatment alternatives, this, 
considering the information in table 2, suggests that we apply a CEA in our evaluation. 
 
Thirdly, there is the Cost-Utility Analysis (CUA) that measures the treatment benefits 
with a generic utility measure. This means that, in addition to the number of life years 
gained, the health related quality of the gained life years are considered. In other 
words both morbidity and mortality is included in the output value. The most common 
health output measure used in CUAs is QALYs. A CUA is a refined version of a CEA 
with a unified output measure enabling comparison of cost-effectiveness from a 
variation of diagnostic areas. Most often the result is presented as cost per gained 
QALY (Drummond et al., 2005). However, QALYs are rarely used when considering 
the benefits of a live birth, as it is vastly complex to estimate. Furthermore, the CEA 
is a better fit to our objective than the CUA as the endpoint is common for both 
treatment alternatives considered. 
 
The fourth and final evaluation method is the Cost –Benefit Analysis (CBA). CBAs 
differ from CEAs and CUAs as the former concentrate on health effects in themselves, 
while the CBA convert the health effects into monetary values. Hence, both the costs 
and the benefits of a treatment are expressed in monetary terms and enables the 
deduction of a net benefit value. A CBA is the most exhaustive form of economic 
evaluation of health care programs, allowing comparison (and thus prioritization) with 
investments in other societal areas, such as construction or education. However, 
assigning a monetary value to a particular health state is not without complexity and 
the risk of measurement errors are therefore considerable. In the context of this thesis, 
it is too complex to estimate the monetary value of a child, an additional human life. 
Therefore no attempt of such calculations will be made which eliminates the CBA for 
this study.  
 
In conclusion, this thesis applies the CEA methodology.  
 
3.2. Cost-Effectiveness Analysis 
In the following sections the CEA is described with more precision. The presented 
methodology is based on Methods for the Economic Evaluation of Health Care 
Programmes by Drummond et al. (2005), unless otherwise stated.  
 
As stated, the CEA is an elaborate economic evaluation that considers both the cost-
side and the benefit-side of the treatment. A CEA is most suitable when decision 
makers face prioritizations between two treatment alternatives and operate under a 
budget restriction. The CEA aims to provide information on what alternative 
maximizes the relevant output. For example, it is the decision maker’s responsibility 
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to supply the population with fertility treatment and the aim is to maximize the 
number of live births with a limited budget.  
 
3.2.1. Perspective 
The first quest is to determine what perspective to apply. The chosen time horizon 
affects what treatment costs and health benefits are included in the evaluation. A 
societal perspective is usually preferred, which is in line with recommendations for 
economic evaluations by the Swedish Dental and Pharmaceutical Benefits Agency 
(TLV) (LFN, 2003).  
 
3.2.2. Costs 
When a perspective is determined the relevant costs and health benefits should be 
identified, measured and valued. When valuing individual costs it is important to 
consider that the true cost might not be equivalent to its market price. This is true for 
most input items, especially in universal health care systems where prices are 
monopolistically projected in addition to often being heavily subsidized. A reasonable 
evaluation of found unit prices should thus be conducted before used in the 
calculations. Moreover, costs that are not specific to the treatment per se, but to the 
overall health care organization should be considered. These are called overhead (OH) 
costs and include entries such as electricity, facilities, administrative costs etc.  
 
3.2.3. Health benefits 
The effectiveness data used in a CEA can be abstracted from existing, quality assured, 
clinical studies or directly withdrawn trough statistical registers. It is of importance to 
consider the inclusion criteria of the clinical trial if such effectiveness data is used. If 
there is uncertainty regarding the quality of the effectiveness data, the efficacy 
variables should be varied in a sensitivity analysis.  
 
When retrieving effectiveness data from existing studies, a different endpoint from 
what we are interested of might be used. In assisted reproduction many studies focus 
on cost per IVF cycle or cost per pregnancy. However, the present study is interesting 
in cost per live birth as a live birth is the actual purpose with fertility treatment. If the 
correct endpoint is missing one can turn to other studies to extract a link between two 
health stages, or the intermediate and final endpoint. For example, there can be other 
existing studies that present usable information regarding how many clinical 
pregnancies following ART-treatment result in a live birth.  
 
3.2.4. Discounting 
In economic evaluations of projects with long time horizons, or with spillover health 
benefits or include costs for years to come costs and benefits are discounted in order 
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to obtain the present value of the project. Discounting aggregates costs and benefits 
that occur in different time periods (Boardman et al., 2011). One cycle of fertility 
treatment, including a 9-month pregnancy, takes about a year. And as discounting is a 
year-to-year adjustment discounting is not applicable to the calculations of this study. 
 
3.3. Incremental cost-effectiveness ratios 
CEAs compare two treatment alternatives and often use incremental cost-
effectiveness ratios (ICER) to present its results. An ICER presents the new 
treatments cost, treatment A, relative to the cost of the old treatment, treatment B, as 
well as treatment A’s health effect relative to that of treatment B. The ICER is 
calculated through the following formula; 
 
𝐼𝐶𝐸𝑅 =  
𝐶𝑜𝑠𝑡𝑠𝐴 −  𝐶𝑜𝑠𝑡𝑠𝐵
𝐸𝑓𝑓𝑒𝑐𝑡𝑠𝐴 − 𝐸𝑓𝑓𝑒𝑐𝑡𝑠𝐵
=  
∆𝐶
∆𝐸
 
 
Additionally, it is a requirement that the two treatments included in an ICER are 
mutually exclusive, which means that if a patient receives one of the treatments, 
he/she cannot receive the other, also treatments are assumed to be independent of each 
other. These characteristics ensure that the costs and effects of another treatment do 
not affect costs and effects of a treatment, which is vital for this type of analysis.  
 
There are four potential outcomes of a ICER demonstrated in the ICER plane in figure 
1; (Q1) treatment A has higher costs but lower effects than treatment B and is 
dominated by treatment B, (Q2) treatment A has higher costs and higher effects than 
treatment B, (Q3) treatment A has lower costs and lower effect than treatment B, and 
(Q4) treatment A has lower costs but higher effects, then it dominates treatment B. In 
case (Q1) and (Q4), one treatment dominates the other and the relative cost-
effectiveness is given. The implication of case (Q2) and (Q3) however, is ambiguous 
and the cost-effectiveness depends on what given monetary treshold is considered 
cost-effective (Drummond et al., 2005).  
 
 
  
 
 
 
 
 
 
 
 
 
Q1 
Dominated 
COSTS 
EFFECTS 
Potential 
treshold 
Cost-effective to 
given treshold 
Q4 
Dominates 
 
       Q3 
Ambiguous 
       Q2 
Ambiguous 
Figure 1. ICER plane 
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The monetary threshold for cost-effectiveness represents the willingness to pay 
(WTP) for the achieved health improvement. Ideally the WTP is equivalent to the 
opportunity cost of implementing the treatment, i.e. the economic value of the 
treatment already in place from which the new treatment would draw resources if 
implemented. Hence, a new treatment would be implemented due to cost-
effectiveness if it brings more health than an already existing treatment with the same 
cost (SBU, 2013). Whether a treatment is regarded cost-effective depends on which 
side of the illustrated threshold-slope (figure 1) the ICER estimates end up. The 
threshold slope represents the highest acceptable ICER, i.e. the highest acceptable 
WTP, for a specific treatment. Better health effects allows for higher costs. 
 
In some countries national guidelines state a fixed monetary value of the ICER-
threshold when conducting CUAs and using QALYs as the health effect estimate. For 
example, in England the National Institute for Health and Clinical Excellence (NICE) 
has used an ICER-threshold in the range SEK 200 000 – 300 0008 since 1998 (NICE, 
2008). However, there is no official ICER-threshold in Sweden even though SEK 
655 000 has been discussed as an appropriate limit. The NBHW has published an 
indicatory guideline presented in table 3, describing what is viewed as a low or a high 
price per QALY gained (Socialstyrelsen, 2008). In practice, the ICER-limits rather 
depend on the severity of the disease as well as its prevalence in the population.  
 
Table 3. Discussed ICER thresholds 
Amount (SEK) Indication 
< 100 000 Low cost per QALY gained 
100 000 – 499 999  Moderate cost per QALY gained 
500 000 – 999 999  High cost per QALY gained 
> 1 000 000  Very high cost per QALY gained 
Source: Socialstyrelsen, 2008 
 
3.4. The applied method 
As the objective of this study is to establish which allocation of ART treatment is 
most cost-effective an economic evaluation will be pursued. The health benefits of the 
two treatment alternatives evaluated is mutual to both treatment alternatives and 
measured in the natural unit live births. Therefore it is natural to apply the CEA 
method. The CEA is suitable when decision makers face a prioritization between two 
treatment alternatives and operate under a budget restriction, which is the case in this 
study. The results of the evaluation will be presented as cost per live birth for both 
treatments, which in turn will be compared in an ICER.   
 
Treatment costs are collected from a public price list published by SRC, which 
includes specific numbers for the RMC clinic. The costs are assumed to equal the true 
                                                        
8 An approximation after converting the original interval £20.000-£30.000 using the equivalent to, 
using the exchange rate of July 1st 2013 being SEK 10.1379/£1 (www.riksbank.se) 
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treatment costs and include OH costs, and are therefore left unadjusted. Some indirect 
costs in the form of transportation costs and production loss under treatment are 
identified and included. All costs will be presented in 2013 SEK.  
 
The effectiveness data are retrieved from RMCs internal statistical database and 
supplemented with national information collected from the Swedish Quality Register 
Q-IVF (2013). The target treatment outcome was a live birth, which was the sole 
focus of the analysis. HRQoL measures were excluded, as they were argumentatively 
redundant.  
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4. DESCRIPTIVE STATISTICS 
To study the relationship between age and cost-effectiveness of ART-treatment we 
have reviewed data from the Reproductive Medicine Center in Malmö, RMC. The 
data is non-experimental and collected for statistical purposes for the clinic. The 
collection period stretches from 1st of January 2011 to 30th of June 2012, and refer to 
the time of initiated treatment cycle. Even though the included data covers a relatively 
short time span, the inclusion choice is motivated by the lack of qualitative data prior 
to 2011 and that the outcome of treatment occur nine months after a full treatment 
cycle (i.e. late spring 2013 for the cycles started at the end of our observation period). 
Therefore the chosen duration period brought the most consistent and reliable data set. 
Only treatments with the couples’ own gametes were included in the data set, while 
cycles with donated eggs or sperm (e.g. lesbian couples) were excluded. This was 
done in an attempt to separate the effect of age on fertility from that of other aspects, 
such as sexual orientation or a medical diagnosis.  
 
Furthermore, the original data set contained couples where the woman is aged 21-41. 
Current regulations at RMC, however, state that only females under the age 39 are 
provided with treatment. Therefore, and because the sample is very small in the older 
age groups, women aged 39-41 are excluded from our data set. Average female age in 
our remaining sample is 32.4 years old. 
 
Table 4. Treated patients 
Female age Observed 
patients a 
Patients per 
year 
<35 764 509 
35 79 53 
36 87 58 
37 79 53 
38 84 56 
Total 1 093 729 
a after exclusions  
 
In the original data set possible ART-treatments consists of IVF, ICSI or a 
combination of both. Since it is impossible to know the allocation between ICSI and 
IVF in the treatment type combination these cycles (n=11) were excluded from our 
sample in order to maximize the accuracy on the most common treatments 
alternatives, ICSI and IVF.  
 
These exclusions reduces our sample from 1200 couples to 1093. For the remaining 
patients a total of 2103 treatment cycles were observed (1.93 treatments per couple), 
out of which 97.8% (n=2057) reached egg aspiration. The live births counted 364 and 
generated a success rate of 17,3% per initiated treatment cycle.  
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A majority of the couples had more than one treatment. However, it is important to 
note that our limited duration for data collection implies that couples may have started 
their ART-treatment before and may continue with their treatment after, our observed 
time period. Therefore we are from our own data alone unable to state the average 
number of cycles per couple. 
 
As the proposed treatment regime, the Medical Screening Program, include females 
up to 42 years old and the reliable RMC data only stretches to age 38, we turn to a 
national registry for assistance. The national quality register of fertility treatments (Q-
IVF, 2013) gathers information from all fertility clinics in Sweden. The data includes 
age-specific information, it explicitly specifies how far along in the treatment 
individual cycles get and it is divided between treatments with donated or own 
gametes. These details enable a comparison between RMC data and the national data. 
However, there are some divergences between the data sets regarding the inclusion 
criteria of the fertility centers, as previously shown in table 1. Additionally, the Q-IVF 
data includes both public and private clinics. This implies that couples who are 
declined publically funded ART-treatment can turn to a private clinic and fund the 
treatment out-of-pocket. If a couple already has mutual children it generally increases 
the chances for ART-treatment to work, thus improving the success rate for private 
clinics compared to public ones such as RMC. Yet, the Q-IVF is the only available 
complement to our RMC data and is therefore used where the RMC data is lacking 
(i.e. for  females aged 39-42). However, to be explicit about the differences of the data 
sets a simultaneous analysis on pure Q-IVF data will accompany the RMC based 
analysis throughout the thesis.  
 
An overview of both data sets is presented in table 5 below. The RMC data has a 
lower success rate for both ICSI and IVF treatments than the national statistics. 
Although the relation between ICSI and IVF is pointing in the same direction, i.e. IVF 
has a slightly higher success rate than ICSI in both samples.  
 
Table 5. Success rate per treatment type and data set 
Data set Treatment 
type 
Number of 
treatments 
Live births Success 
rate 
RMC     
 IVF 1 220 203 16,6% 
 ICSI 883 161 18,2% 
 Total 2 103 364 17,3% 
Q-IVF     
 IVF 8 054 1 628 20,2% 
 ICSI 8 806 1 852 21,0% 
 Total 16 860 3 480 20,6% 
 
 
Note that the endpoint of this study is live births, as the cure when treating infertility 
is a child. Therefore we will not make any difference between single ETs and double 
ETs, or multiple or single births. This implies that a twin birth will count as one 
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childbirth, i.e. one successful treatment. This assumption is partly made due to the 
risks of a twin birth after the first cycle generating a success rate of 200%, but the 
primary reason is that we aim to explore the cost of treating infertility for a couple 
irrespective of how many children they conceive.  
 
Success rates show the possibility of having a live birth per started treatment, which 
means that if treatments are repeated the cumulative success rate will be higher. 
Olivius et al. (2002) studied the relationship between numbers of treatment cycles and 
cumulative success rate, showing that more than 50% of all couples undergoing at 
least three ART-treatments would get pregnant. Due to the limited duration of our 
observed period we were unable to follow individual couples throughout their whole 
treatment process to determine the success rate per treated couple. The solution is to 
estimate the success rate per cycle and then use the number of subsidized treatment 
cycles (three) to determine the overall success rate per couple. The cumulative success 
rate after three cycles was estimated using Kaplan-Meier product limit estimate; 
 
[1 − (1 − 𝑝1)(1 − 𝑝2)(1 − 𝑝3)] ∗ 100%  
 
where px is the probability of achieving live birth in cycle x (Olivius et al. 2002). As 
mentioned there was no data on cycle-specific success rate and the average success 
rate for each female age was therefore used for each px. 
 
The use of three cycles in the cumulative success rate estimation, even though clearly 
not all couples utilize all provided cycles, is motivated by the assumption that the 
couples who do not pursue the third cycle are those who have already achieved a live 
birth. There is a portion of patients who opt out of treatment due to other reasons than 
a live birth, but those cases were assumed marginal and thus disregarded. Adding up 
the success rates for each cycle leaves us with the success rate per couple. The results 
are presented in table 6 and show a declining cumulative success rate with increasing 
age. 
  
Table 6. Observed and cumulative success rates 
Female 
age 
Observed success rate Cumulative success rate 
Strict age limit (<39) MS program  Strict age limit (<39) MS program  
RMC Q-IVF RMC a Q-IVF RMC Q-IVF RMC a Q-IVF 
<35 19,1% 26,2% 19,1% 26,2% 47,0% 59,7% 47,0% 59,7% 
35 17,9% 21,0% 22,8% 22,0% 44,6% 50,8% 54,0% 52,5% 
36 12,7% 21,0% 15,4% 22,0% 33,4% 50,8% 39,5% 52,5% 
37 11,3% 21,0% 13,2% 22,0% 30,1% 50,8% 34,6% 52,5% 
38 11,5% 15,3% 14,8% 16,2% 30,6% 39,3% 38,2% 41,2% 
39  - - 16,2% 16,2% - - 41,2% 41,2% 
40  - - 16,0% 16,0% - - 40,7% 40,7% 
41  - - 16,0% 16,0% - - 40,7% 40,7% 
42  - - 7,5% 7,5% - - 20,8% 20,8% 
a Success rate data for women aged 39-42 was drawn from Q-IVF due to lack of RMC clinic data 
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The point of the proposed Medical Screening Program, including medical screening 
for women aged 35-42, is to improve the success rate of the individual couples that 
qualify for subsidized ART-treatment. As the end point of the suggested medical 
screening is whether or not the treatment reaches satisfactory egg aspiration the 
observed success rate for the Medical Screening Program refer to success rates per 
egg aspiration, which was then used to calculate the cumulative success rate for the 
Medical Screening Program.  As shown in table 6 the cumulative success rate, except 
for the 42-year olds, vary between 30-60%. This range corresponds to the findings of 
previous studies where the success rate over three consecutive ART-cycles varied 
from 34 to 65% (Witsenburg et al., 2005; Malizia et al., 2013; Mol et al., 2000; 
Stewart et al., 2011; Elizur et al., 2006), the most relevant being a Swedish study 
conducted by Olivius et al. (2002) presenting a cumulative success rate rate of 63% 
for the overall population.  
 
Additionally, table 6 illustrates the common problem of higher age on fertility rates. 
Several studies suggest that the female age is negatively correlated to success rates 
(Kenny 1994; Griffiths et al., 2010; Broekmans et al., 2004; Wright et al., 2005; 
Templeton et al., 1996; Olivius 2009). A regression analysis of our RMC data 
confirms the implications of the table above and shows a significant negative 
relationship between female age and live births.  
 
Table 7. Regression analysis for success rates 
Probit model 
Live birth Coefficient Robust std. errors 
Age -0.032*** 0.008 
ICSI=1, IVF=0 -0.023 0.068 
Fresh=1, Frozen=0 0.501*** 0.079 
Interruption pre-egg asrationpi=1, no 
interruption=0 
omitted - 
Interruption pre-ET=1,  
no interruption=0 
omitted - 
Constant -0.132 0.264 
Chi squared-statistic 0.000  
Pseudo R2 0.031  
Number of observations 1839   
Note: * = α< 10%, ** = α< 5%, *** = α<1% 
 
The regression analysis, in table 7, is conducted through using models for binary 
dependent variables since our outcome, live birth, can only take the value 1 for live 
birth or 0 for no live birth. For this reason we have used a probit regression model. 
The independent variable age is the only variable that is not binary in our regression. 
All of the other variables are binary to test if the outcome is depending on difference 
between IVF/ICSI, fresh/frozen embryos, if egg aspiration or not and if ET or not. 
The results from the probit model suggest that, as previously stated, age has a 
negative impact on live births. It also concludes that fresh cycles has a positive impact 
on live births (compared to thawed) and that the treatment type, ICSI or IVF, is 
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irrelevant to the outcome of a live birth. These results are equivalent to the statistics 
for each parameter in our sample. The variables of failed treatment pre-egg aspiration 
or pre-ET is omitted from the regression since both predicts failure perfectly. Data 
matching these variables =1 are excluded from the regression data. 
 
Another factor affecting female fertility is BMI. However, one of the treatment 
conditions at RMC is for the woman to have a BMI below 30. The BMI restriction 
will be included the Medical Screening Program too, and the BMI effect will thus be 
equivalent for the two treatment alternatives. The effect of BMI on success rate is 
hence dealt with in the inclusion criteria for treatment and is therefore not further 
discussed in this thesis.  
 
Our RMC sample of 2103 individual cycles is divided according to table 8 below, and 
as shown, success rate is higher for fresh treatments than for treatments with thawed 
embryos. The success rate for fresh cycles, both IVF and ICSI treatments are 
equivalent between our sample and the national register data. Although, in our sample 
there is a large difference between fresh and thawed cycles, while the difference is 
much smaller in the national data set. In the regression analysis (table 7) the results 
for fresh or frozen embryos are significant, which suggests that whether the cycle is 
fresh or thawed has a significant impact on live births. Remember however that even 
though the results are significant in the RMC sample that might not be the case for the 
Q-IVF data. 
 
Table 8. Success rate per type of treatment 
Data set   Cycles Live births Success rate 
RMC      
 
IVF Fresh 632 134 21.2% 
 
 Thawed 251 27 10.8% 
 
ICSI Fresh 827 164 19.8% 
 
 Thawed 393 39 9.9% 
Q-IVF  
    
 
IVF Fresh 5838 1330 22.8% 
 
 Thawed 2426 441 18.2% 
 
 
ICSI Fresh 5754 1301 22.6% 
 
 Thawed 3094 607 19.6% 
Sourse: Q-IVF, 2013 
 
As this thesis aims to study the economic consequences of implementing a new 
treatment regimen in the ART field we have to calculate the expected outcome of the 
new proposal, the Medical Screening Program. The main difference from today’s 
structure is the additional medical screening for the couples where the woman is 
above 35 years, from which only those suitable for treatment will be selected to 
continue ART-treatment. Additionally, the Medical Screening Program would 
introduce publically funded ART-treatment for women aged 39-42.  
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Table 9. Yearly demand for ART-treatment 
Female age Observed Extrapolated Total 
<35 509  509 
35 53  53 
36 58  58 
37 53  53 
38 56  56 
39  53 53 
40  51 51 
41  50 50 
42   49 49 
Total 931 
 
To be able to calculate the cost per live birth for each treatment program the age 
allocation of the population group is of interest. The age allocation is important as 
older women have lower success rates and thus face diverging cost structures from 
that of younger women. Since our sample only contains couples where the woman is 
<39 years old we had to extrapolate the demand of ART-treatments for women aged 
39 and above.  The demand was extrapolated using a linear relationship with a R2 of 
0.369, and adjusted to a yearly demand (see table 9). 
 
For couples to qualify for treatment in the Medical Screening Program the woman 
need to have at least four oocytes for retrieval after hormone therapy (i.e. the pre-egg 
aspiration ultrasound has to testify of at least four maturing oocytes). To estimate the 
portion of patients per age group who will qualify for further treatment in the Medical 
Screening Program we rely on data from Ferraretti et al (2011). The study is based on 
Italian data, but after consulting the medical experts at RMC9 we find it reasonable to 
apply in a Swedish setting, and thus we proceed using the medical screening 
qualification rates presented in table 10. If combining the yearly demand with the 
qualification rate, we find the qualified demand for the Medical Screening Program 
(see results).  
 
 
Table 10. Qualification rates of medical screening 
Female age 
<4 oocytes (disqualified in 
Medical Screening) 
MS qualification rate 
<30 8% 92% 
30-35 11% 89% 
36-39 14% 86% 
40-42 23% 77% 
>42 38% 62% 
Source: Ferraretti et al.,2011 
 
In the forthcoming calculations we keep using both RMC and Q-IVF data to enable 
comparisons and inference about possible differences, as previously announced in this 
section.  
                                                        
9 Personal correspondence with Aleksander Giwercman and Mona Bungum 
29 
 
5. COSTS AND COST CALCULATIONS 
Couples undergoing fertility treatment at RMC in Malmö are allocated between a long 
and a short treatment protocol. Approximately 60% of the couples are treated 
according to the long protocol while the remaining 40% follow the short protocol. 
There are no age differences in the protocol allocation10.  
 
Each protocol follow its respective treatment steps listed in table 11 below. The main 
difference is that females treated with the long protocol undergo a down-regulation of 
her natural hormones before starting hormone stimulation, in order to neutralize the 
natural hormones and facilitate a positive treatment outcome. This step is ruled 
unnecessary for some women that are therefor referred to the short protocol. The short 
protocol, on the other hand, includes antagonist medication, preventing the maturing 
eggs from being released prematurely. Both treatment protocols include an ovulation 
trigger that promotes ovulation at the ideal time for the scheduled egg aspiration 
(RMC, 2012:I).  
 
Table 11. Treatment schedule 
LONG PROTOCOL  SHORT PROTOCOL 
 
 
Description  Step Description 
1 Examination including ultrasound (F) a 
M
E
D
IC
A
L
 S
C
R
E
E
N
IN
G
 1 Examination including ultrasound (F) a 
Andrological examination (M) a Andrological examination (M) a 
Sperm sample Sperm sample 
2 Consultation, treatment planning (physician) 
and treatment information (nurse) 
2 Consultation, treatment planning (physician) 
and treatment information (nurse) 
3 Down regulation  3 Hormone stimulation 
4 Hormone stimulation 4 Antagonist 
5 Estradiol blood test (F)a 5 Estradiol blood test (F)a 
6 Ultrasound (1-3) 6 Ultrasound (1-3) 
7 Ovulation trigger  7 Ovulation trigger 
8 Egg retrieval, incl. sperm sample and analysis  8 Egg retrieval, incl. sperm sample and 
analysis 
9 ICSI or IVF  9 ICSI or IVF 
10 Embryo transfer  10 Embryo transfer 
11 Follow up treatment - hormone stimulation  11 Follow up treatment - hormone stimulation 
12 Pregnancy test   12 Pregnancy test  
13 Early pregnancy ultrasound (if positive 
pregnancy test) 
 13 Early pregnancy ultrasound (if positive 
pregnancy test) 
a F indicates female patient; M indicates male patient 
 
The protocols and their treatment steps help to identify what resources are used in the 
treatment and at what point they occur, which is why the protocols are presented yet 
again. In the next sections the resource units and their corresponding costs will be 
explored as well as how they are estimated and included in the treatment cost 
calculations.  
 
                                                        
10 Personal correspondence with Margareta Kitlinski 
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Henceforth, the allocation of 60% of patients to the long protocol and the remaining 
40% to the short protocol is included in all cost calculations and not further mentioned 
in detail.  
 
5.1. Unit costs 
The perspective of this analysis is societal, i.e. all costs and consequences, no matter 
to whom they accrue (patient/health care/society), are included (Drummond, 2005; 
Morris, 2012; Boardman 2011). On the cost-side this implies that both direct and 
indirect costs are identified and calculated. For example, direct medical costs include 
doctor time, equipment and OH costs (administration, facilities etc). Moreover cost of 
pharmaceuticals and the societal cost of production loss is calculated as well as direct 
transportation costs at RMC visits. 
 
Table 12. Unit costs in 2013 SEK 
Cost Category Cost Unit Source 
Direct health care costs 
Physician examination including ultrasound 3 134 Per visit SHCR pricelist 
Initial blood work a 610 Per patient SHCR pricelist 
Andrological examination (M) 4 740 Per visit  SHCR pricelist 
Sperm sample 1 438 Per sample SHCR pricelist 
Sperm analysis 1 700 Per sample SHCR pricelist 
Physician consultation 1 714 Per visit SHCR pricelist 
Nurse consultation 1 419 Per visit SHCR pricelist 
Nurse visit 493 Per visit SHCR pricelist 
Estradiol blood test 36 Per test SHCR pricelist 
Ultrasound (HyCoSy) 2 180 Per visit SHCR pricelist 
     IVF, completed 22 176 Per treatment SHCR pricelist 
      IVF, aborted pre-embryo transfer  1 758 Per treatment SHCR pricelist 
     IVF, aborted pre-egg aspiration 481 Per treatment  SHCR pricelist 
     ICSI, completed 28 325 Per treatment  SHCR pricelist 
     ICSI, aborted pre-embryo transfer  2 976 Per treatment  SHCR pricelist 
     ICSI, aborted pre-egg aspiration 481 Per treatment  SHCR pricelist 
Thawed embryo transfer 12 529 Per treatment SHCR pricelist 
Pregnancy test 45 Per test SHCR pricelist 
Ultrasound visit (physician) 1 420 Per visit SHCR pricelist 
Cost of Pharmaceuticals 
Down regulation a 1 135 Per patient FASS 
Hormone stimulation a    
     <35 3 344 Per patient FASS 
     >35  7 443 Per patient FASS 
Antagonist a 1 977 Per patient FASS 
Ovulation trigger a 342 Per patient FASS 
Pharmaceutical use at egg retrieval a 26 Per egg retrieval FASS 
Follow-up treatment, fresh cycle a 506 Per patient FASS 
Follow-up treatment, thawed cycle a 877 Per patient FASS 
Direct non-medical costs 
Transportation cost, RMC round trip 210 Per round-trip Google Maps, Swedish Tax Agency 
Indirect costs 
Production loss b 263 Per hour Statistics Sweden, Ekonomifakta 
a For more details on pharmaceuticals and cost calculations, see appendix 11.3. 
b Social benefit costs of 42% (Ekonomifakta) was added to average wage (Statistics Sweden, 2013). 160 work hours per month 
was assumed.  
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The unit costs are presented in table 12. All costs found in another currency than 
Swedish Kronor or presented in a price level other than SEK 2013 were firstly 
converted through the applicable exchange rate and then adjusted to the 2013 price 
levels through CPI.  
 
The direct health care unit costs were gathered from the official 2013 price list of the 
Southern Health Care Region, where prices include OH costs.  As mentioned, it is not 
necessarily the case that official prices translate into actual costs, especially for 
publically funded health care units. However, since these are the only prices available 
and they are used within the universal health care system to debit other regions (when 
health care services are utilized across regions) we view them as accurate cost 
estimates.  
 
The pharmaceutical unit costs were found at FASS (2013) while information on the 
indirect costs was collected from Statistics Sweden (2013) and the statistical platform 
website Ekonomifakta (2013). Transportation costs were calculated with help from 
distance searches at Google Maps and current reimbursement levels of the Swedish 
tax Agency.  
 
5.1.1. Pharmaceuticals 
Medical professionals at RMC identified the pharmaceuticals, and quantities, used 
throughout ART-treatment11. Unit costs were found after converting package costs 
retrieved from the private-public partnership FASS, the Swedish Medicines 
Information Engine. The hormone stimulation-doses vary with age, which makes the 
use of some pharmaceuticals age dependent12. See appendix table 22 for a more 
detailed description.  
 
5.1.2. Direct medical costs 
The direct costs of publically founded ART-treatment are related to medical visits at 
RMC. A small portion of these costs fall on the patients with out-of-pocket payments 
per visit (approximately SEK 200 per visit) while the majority is publically funded by 
the health care system (Vårdguiden, 2013). This cost division of medical visits will 
not be discussed further since it is the total societal cost per live birth that is of interest 
in this analysis.   
 
5.1.3. Direct non-medical costs  
For the couple to attend the medical appointment they have to take time off work and 
transport themselves to the visit, implying two types of costs accrued to the treated 
couple. Production loss will be further dealt with in the following section.  
                                                        
11 Personal correspondence with Margareta Kitlinski 
12 Personal correspondence with Margareta Kitlinski 
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Transportation costs are, although non-medical, direct costs paid by the couple. To 
estimate the transportation costs per RMC visit, geographical distance, population 
distribution in the Southern Health Care Region and governmental travel refunding 
levels were considered. The distance from Malmö to the largest city in each county 
was established using Google Maps and works as a proxy for the average distance for 
that county’s inhabitants. In Skåne County the second largest city Helsingborg used to 
calculate average distances for the Skåne population. This was done since Malmö, 
hosting the RMC clinic, would generate a distance of zero kilometers for all enrolled 
Skåne couples, which was held as unlikely. The geographical distribution of couples 
seeking ART-treatment was assumed to follow the population distribution between 
the counties in the Southern Health Care Region, as no details regarding actual 
residence was available. Using the weighted county-population, an average distance 
of 104km to the RMC clinic was found. 
 
To specify the cost per travel distance (km) the couple was assumed to drive, and 
share, a car. As an estimation of the average travel cost per distance (km), the amount 
deductible per commute-kilometer in the income declaration according to the Swedish 
Tax Agency was adopted; SEK 18.50 per 10km (Skatteverket, 2013). This brought a 
lower average cost than with travel by public transportation and was thus applies in 
our calculations in order to preclude overestimation of the transportation costs. The 
transportation costs were found to be SEK 210 per couple and visit, i.e. the cost per 
round-trip.  
 
The transportation cost was only included in the treatment costs when the medical 
visit is located at RMC. Some physician visits per full ART-treatment-cycle can be 
placed in the local primary care (such as the pregnancy test), in case of which the 
transportation cost was assumed to be negligible and therefore set to zero. 
 
5.1.4. Production loss 
When the couple takes time off work to attend treatment visits, there is an indirect 
loss both to the couple themselves and to their employer. The couple looses income 
and the employer looses the production the employee would have produced if 
remaining at work. A generally accepted method to calculate production loss in health 
economic evaluations is the human capital (HC) approach. The HC approach is 
recommended for economic evaluations by Swedish authorities and is thus the natural 
methodological choice of this analysis (LFN, 2003). The HC approach estimates the 
monetary value time to equal the cost of an employee to an employer. Wages and 
other costs, such as pension fees, are included (Boardman et al., 2011; Drummond et 
al., 2005).  
 
It is assumed that both the man and the woman in a couple undergoing ART-treatment 
take the same amount of time off work, as RMC stretches the importance of the 
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treatment being a shared effort and thus the couple is assumed to be equally dedicated 
to the treatment (RMC, 2012:II). The man is therefore assumed to accompany the 
woman to the egg aspiration appointment and so on. Therefore the hourly production 
loss is held gender neutral.  
 
In agreement with the recommendation by Drummond et al. (2005) the general wage 
rate for both men and women was used. The average monthly income from work in 
Sweden 2012 was adjusted to 2013 numbers using CPI. The adjusted average monthly 
income was SEK 29 805 (Statistics Sweden, 2013). Assuming 160 work hours per 
month, the average hourly wage rate in 2013 was SEK 186. In addition, payroll taxes 
of 42 percent were added including an average of pension fees for different types of 
employees (Ekonomifakta, 2013). These calculations generated an hourly cost of an 
employee of SEK 263, which was then set equivalent to the production loss according 
to the HC approach.  
 
Production loss occurs at every medical visit, both for the actual visit and for the 
traveling time to and from the clinic. The RMC visits were assumed to take one hour 
on average and a one-hour travel to and from the appointment was assumed (2h round 
trip). Adding up that makes three-hours per RMC visit and person, generating a six-
hour production loss per RMC visit and couple. For visits to a local primary care 
center a one-hour visit was again assumed but the traveling distance, and therefore 
also the traveling time, was viewed as negligible and set to zero.  
 
5.2. Resource use  
In order to convey the resource consumption in ART-treatment a list of resource use 
is presented in the table below. The indicated quantity consumed of each resource 
refers to a full (completed) cycle. As previously stated there are several points in a 
treatment cycle where disturbance can occur forcing discontinuation of treatment. 
This has not been taken into consideration in table 13 below.  For a more detailed 
example of the calculations of an average cycle cost including discontinuation 
probabilities, see appendix table 30.  
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Table 13. Resource use in a full ART-treatment cycle 
5.3. Cost of medical screening 
As the proposed change in the subsidized ART-treatment program contains a medical 
screening in order to determine whether a female aged 35-42 qualifies for state-
funded treatment it is of interest to determine the cost of said screening process.  
 
The Medical Screening Program would cover treatment steps 1 through 6 as presented 
in the protocol overview in table 11. The cost of a medical screening thus follows the 
cycle up to the point of the ultrasound where the ovarian growth is examined and the 
responsiveness to treatment is determined. When calculating the costs of medical 
screening only the patient groups >35 were considered, as they are the ones affected 
by the proposed program change.  The cost of medical screening, regardless if the 
women qualifies for further treatment or not, is SEK 40 070.   
 
Table 14. Cost of medical screening 
Female 
age 
Age neutral costs 
Hormone 
stimulation 
Total Direct 
medical 
costs  
Pharmaceuticals Transportation 
cost 
Production 
loss 
<35 20 386 1 472 1 050 9 211 4 344 36  463 
>35 20 386 1 472 1 050 9 211 7 951 40 070 
 
5.4. Cycle variations 
The Southern Health Care Region provides a maximum of three fresh ART-treatment 
cycles.  Thawed cycles are offered if there are frozen embryos available from a 
Resource 
Units used, full cycle 
C1 C2&C3 (fresh) C2&C3 (thawed) 
Physician examination including ultrasound 1 0 0 
Initial blood work 1 0 0 
Andrological examination (M) 1 0 0 
Sperm sample 2 0 0 
Sperm analysis 2 0 0 
Physician consultation 1 1 1 
Nurse consultation 1 0 0 
Nurse visit 2 2 1 
Estradiol blood test 1 1 0 
Ultrasound (HyCoSy) 1,925 1,925 0 
     IVF 0,43 0,43 1 
     ICSI 0,57 0,57 1 
Thawed embryo transfer 0 0 1 
Pregnancy test 1 1 1 
Ultrasound visit (physician) 1 1 1 
Nafarelin  0,6 0,6 0 
Hormone stimulation f 1 1 0,4 
Ganirelix 0,4 0,4 0 
Chorionic gonadotrophin alpha 1 1 0 
Pharmaceutical use at egg retrieval 1 1 0 
Transportation to RMC, round trip 8,925 5,925 3 
Patient production loss, hours 60,55 54,55 22 
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previous cycle. In the age-dependent treatment cost calculations all treatment 
outcomes and costs are weighed after treatment type – fresh IVF, fresh ICSI and 
thawed IVF or ICSI – and their respective success rates. Calculations are also adjusted 
for long or short protocol costs.  
 
Additionally, the corresponding cycle costs for each treatment step may vary between 
the first, second and third cycle. The main reason being the availability of thawed 
cycles but also because there is less need for informative meetings with medical 
professionals when the treatment is repeated. These variations are included in the 
treatment cost calculations. 
  
All age-related variations – success rates, cycle type and protocol continuation – result 
in an age-dependent variation in cost per live birth.  The success rates affect how 
many treatments are required to attain a live birth, the cycle type determines the cost 
of said cycle and the protocol continuation determines how far along into the protocol 
the treatment is interrupted (discontinued).  All of these factors are included in the 
treatment costs.  
 
It is noteworthy that the age-related cost difference may not be as straightforward as 
one might initially think. The fact that younger patients have higher success rates is 
not the only aspect influencing the cost per live birth. Older patients have higher 
discontinuation rate for each treatment step, and thus face a lower cost per started 
treatment cycle, counteracting the fact that younger patients have higher success rates. 
For example, a woman aged 34 has a higher chance of having a successful treatment 
than a woman of 40, but she also has a higher probability of getting relatively far in 
the treatment protocol without actually reaching a live birth, whereas the older woman 
has a higher risk of early treatment discontinuation which is a less costly treatment 
attempt.  
 
5.5. Calculating cost per live birth  
When calculating the cost per live birth following ART-treatment there are two sides 
to consider; the treatment cost and the number of live births.  
As we are interested of the total treatment cost of each couple the cost per each 
specific cycle type was calculated, weighted and summed. The first cycle was 
assumed to be a fresh cycle, as thawed cycles require a frozen embryo from previous 
cycles. In the first cycle the age-specific allocation between the IVF and the ICSI 
method and their respective success rates and discontinuation rates were implemented 
and the corresponding costs were weighted accordingly. The same method was used 
in calculating the cost of cycle two and three, although with the inclusion of thawed 
cycles. In cycle two and three the fresh cycles were made less costly than in cycle one, 
as consultative medical visits and sperm sample analysis were viewed as redundant.  
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Further, an average of 2.39 cycles per couple was employed according to the findings 
of a study of ART-treatment at Sahlgrenska University hospital (Olivius et al., 2002). 
Other previous studies have found the average number of treatment cycles in the 2 to 
3 range (Witsenburg et al., 2005; Malizia et al., 2013; Mol et al., 2000; Stewart et al., 
2011; Elizur et al., 2006), verifying the validity of the 2,39 estimate. Consequently the 
weighted cost of the first cycle was then summed with 1.39 times the weighted cost of 
cycle two and three.  
Additionally, costs of the medical screenings for patients who disqualify for further 
treatment in the Medical Screening Program are incorporated in the program specific 
cost per live birth.  
 
5.6. Exclusions 
This analysis does not include costs of delivery (child birth), nor does it explore the 
possible increase in health care utilization of children conceived through ART-
treatment (Ericson et al., 2002). This implies an assumption of children conceived 
through ART-treatment not being overrepresented in hospital utilization, i.e. not being 
more costly, than naturally conceived children after the conception itself.  
 
These exclusions are verified by the objective of ART-treatment to cure infertility. 
Thus the costs occurring after a child is conceived is irrelevant for the purpose of this 
thesis.   
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6. RESULTS 
6.1. Base case analysis 
The described calculation methods generated the results presented in tables 15 and 16 
below. The results contain calculations based on both the RMC and the Q-IVF data 
set discussed in section 4. The results corresponding to each data set is presented 
separately.  
As previously stated there is an overall societal trend to have children later in life 
(Statistics Sweden, 2012:I). The fact that more couples wish to reproduce at an older 
age implies a high demand for ART-treatment even in ages well above 35. This 
assumption is supported by the extrapolated demand that shows rather consistent 
levels of demand throughout the age groups (table 9). However, it is also well-known 
that fertility decreases with age, especially for women (de la Rochebrochard, 2001; 
Suchartwatnachai et al., 2000; SBU, 2012; SMER, 2013). Hence, when introducing 
the Medical Screening Program, we expect the qualification rate to be negatively 
correlated with age. This expectation is also confirmed in the results, showing a 
declining medical screening qualification rate with age (Ferraretti et al., 2011). This 
trend is universal in our analysis.  
For the same reason as we expected the medical screening qualification rate to fall 
with age it is logical to assume that the cumulative success rate is negatively related to 
age. The declining success rate with age that can be observed for both data sets 
supports this assumption. Remember, however, that the original RMC data lacked 
satisfactory observations for females aged 39-42 and therefore the success rates for 
these age groups were extracted from the Q-IVF data set. This mixture of data in the 
RMC case somewhat confuses the age- success rate relation, as Q-IVF generally has 
higher success rates. 
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Table 15. Base case results using RMC data 
Female 
age 
Treatment demand  
(couples) a 
Cumulative success 
rate 
Expected live births Cost per live birth 
Unrestricted 
demand 
Qualified in 
MS 
program 
Strict age 
limit 
(<39) 
MS 
program b 
Strict age 
limit 
(<39) 
MS 
program b 
Strict age 
limit 
(<39) 
MS 
program b 
<35 509 509 0,47 0,47 239 239 280 739 280 739 
35 53 47 0,45 0,54 24 25 309 934 265 167 
36 58 50 0,33 0,40 19 20 404 326 357 745 
37 53 45 0,30 0,35 16 16 455 846 415 115 
38 56 48 0,31 0,38 17 18 445 432 373 550 
39 53 45 - 0,41 - 19 - 331 153 
40 51 40 - 0,41 - 16 - 351 117 
41 50 39 - 0,41 - 16 - 351 117 
42 49 37 - 0,21 - 8 - 678 754 
Total 931 860 0,43 c 0,45 c 315 377 308 270 310 514 
a Demand was observed at RMC in the time period Jan 2011- June 2012 for female patients aged <39, for 39-42 the presented 
demand is extrapolated. To attain the yearly ART-treatment demand for SHCR the observed demand was divided by 1,5. 
b As the RMC’s supply of treatment is age-restricted to females <39 the RMC data set only contained reliable success rates for 
the females up to 38 years of age. The success rates for females 39-42 are extracted from Q-IVF.  
c Total success rates refer to a weighted population average.  
 
 
Table 16. Base case results using Q-IVF data 
Female 
age 
Treatment demand  
(couples) a 
Cumulative success 
rate 
Expected live births Cost per live birth 
Unrestricted 
demand 
Qualified 
in MS 
program 
Strict age 
limit 
(<39) 
MS 
program 
Strict age 
limit 
(<39) 
MS 
program 
Strict age 
limit (<39) 
MS program 
<35 509 509 0,60 0,60 304 304 217 368 217 368 
35 53 47 0,51 0,53 27 25 261 166 261 814 
36 58 50 0,51 0,53 29 26 256 216 264 804 
37 53 45 0,51 0,53 27 24 258 178 264 804 
38 56 48 0,39 0,41 22 20 328 111 331 152 
39 53 45 - 0,41 - 19 - 331 152 
40 51 40 - 0,41 - 16 - 351 118 
41 50 39 - 0,41 - 16 - 351 118 
42 49 37 - 0,21 - 8 - 678 754 
Total 931 860 0,56 b 0,53 b 409 457 231 646 251 704 
a Demand was observed at RMC in the time period Jan 2011- June 2012 for female patients aged <39, for 39-42 the presented 
demand is extrapolated. To attain the yearly ART-treatment demand for SHCR the observed demand was divided by 1,5. 
b Total success rates refer to a weighted population average.  
 
Introducing the Medical Screening Program translates into excluding patients with 
unsatisfactory response to hormone stimulation, from further treatment. These patients’ 
biological prerequisites are suboptimal for reproduction to be probable, even with the 
assistance of ART-treatment. Hence we expect the success rates to be higher, per age 
group (>35), for patients in the qualified sample than for patients in the Strict Age 
Limit Program where little attention is paid to individual biological and medical 
suitability. These expectations are confirmed in the data but does not eliminate the 
negative correlation between age and success rate, but rather increases each age 
groups internal success rate. The improved success rates are valid for both data sets.  
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Female patients of age 42 show a significantly lower success rate than the other 
patient groups. The success rate diversion affects the weighted success rate on a 
population level for the Medical Screening Program. In spite of this, and because of 
the lower proportion of patients who qualify for treatment in the older age groups, the 
Medical Screening Program shows a higher population success rate for the RMC data 
set. For the Q-IVF data set, however, the Medical Screening Program brings a too 
small improvement in success rate per age group to compensate for the inclusion of 
older patients and the population success rate is thus lower with the Medical 
Screening Program than with the Strict Age Limit Program. 
 
Additionally, the tables clearly states that the Medical Screening Program is superior 
to the Strict Age Limit Program regarding live births generated. This is a natural 
effect as the Medical Screening Program allows for a larger number of treatments, an 
increase from 729 13  to 860 for both data sets, and has a similar, if not higher, 
population success rate.  
 
So far the results are equivalent, or very similar, for the two data sets. Regarding cost 
per live birth, however, there are some differences worth noting. Firstly, the RMC 
data set analysis testifies that introducing the Medical Screening Program would 
increase the average cost per live birth with nearly SEK 3 000 (308 000-311 000) in 
comparison to the Strict Age Limit Program. The corresponding number for the Q-
IVF data set is SEK 20 000 (232 000 – 252 000). An increased number of live births 
thus seem to correspond to a higher cost per live birth. The data sets both state that 
argument even though the results differ in magnitude. These results are expected as 
the couples with the highest probability of reproducing (i.e. younger women with a 
higher medical suitability in general) are already allowed treatment before introducing 
the Medical Screening Program. 
 
To combine the effects of costs and benefits of introducing the Medical Screening 
Program, the results are preferably presented as ICER values. Remember from section 
3.3. that the ICER value presents the change in cost in relation to the change in effect. 
Thus, the ICER value demonstrating the effects of a switch from the Strict Age Limit 
Program to the Medical Screening Program, is defined as; 
 
𝐼𝐶𝐸𝑅 =  
𝐶𝑜𝑠𝑡𝑠𝑀𝑆 − 𝐶𝑜𝑠𝑡𝑠𝐴𝑔𝑒_𝑙𝑖𝑚𝑖𝑡
𝐸𝑓𝑓𝑒𝑐𝑡𝑠𝑀𝑆 − 𝐸𝑓𝑓𝑒𝑐𝑡𝑠𝐴𝑔𝑒_𝑙𝑖𝑚𝑖𝑡
 
And the corresponding ICER values for the RMC and Q-IVF data sets, respectively, 
are;  
𝐼𝐶𝐸𝑅𝑅𝑀𝐶 =  
310 514 − 308 270
377 − 315
= 36 
𝐼𝐶𝐸𝑅𝑄−𝐼𝑉𝐹 =  
251 704 − 231 646
457 − 409
= 42014 
                                                        
13 The sum of unrestricted ART-treatment demand for women <39: 509+53+58+53+56=729 
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As stated both analyses show a rise in cost per live birth and a significant increase in 
number of live births. The increase in the number of live births is 20% (377/315) and 
12% (457/409) for the data sets respectively The interpretation of the ICERRMC 36 per 
additional live birth is such that the average cost per live birth increases with SEK 36 
for each additional child brought to life by the new program. The resulting ICER from 
applying the Q-IVF data set generates a positive value with magnitude 420, 
confirming a cost increase per live birth.  
 
As an increase in the number of live births a the constant aim with ART-treatment, 
while one wishes to keep costs down, the full interpretation of these results will 
depend on what monetary threshold is held cost-effective. Nevertheless, ICER values 
of 36 or 420 state that each additional live birth increases the average cost per live 
birth. But the rise is arguably negligible, especially considering the price tag per live 
birth.  
 
6.2. Cost effects accrued to the Southern Health Care Region 
Above the main results of this thesis, the Medical Screening Program’s effect on cost 
per live birth, were presented while the following section regards the cost effect of the 
Medical Screening Program on the health care region. These subresults are of interest 
for regional decision makers when considering the Medical Screening Program. As 
our target population is the inhabitants of the Southern Health Care Region and the 
evaluated treatment program is that of RMC Malmö, these results are primarily of use 
to decision makers of that particular region.  
In an attempt to depict the costs of the Southern Health Care Region, societal costs 
such as production loss and transportation costs are excluded.  
 
Table 17. Costs to the Southern Health Care Region using the RMC data set 
Female 
age 
Strict age limit (<39) MS program 
Per live birth Expect
ed live 
births 
Cumulative 
cost 
Per live birth Expected 
live 
births 
Cumulative 
cost Hospital 
costs 
Pharma-
ceuticals 
Total 
Hospital 
costs 
Pharma-
ceuticals 
Total 
<35 182 111 26 285 208 396 239 49 860 840 182 111 26 285 208 396 239 49 860 840 
35 191 768 42 046 233 814 24 5 494 886 158 396 39 393 197 789 25 5 008 551 
36 248 556 55 705 304 260 19 5 885 859 209 774 55 410 265 184 20 5 227 373 
37 280 565 62 814 343 379 16 5 442 664 243 899 64 191 308 090 16 4 831 004 
38 273 651 61 529 335 180 17 5 744 062 219 010 57 923 276 932 18 5 099 720 
39   
   
  190 206 52 047 242 253 19 4 525 026 
40   
   
  193 838 60 084 253 922 16 4 087 896 
41   
   
  193 838 60 084 253 922 16 3 981 717 
42           372 361 88 223 460 583 8 3 582 897 
Total 196 842  33 021  229 863  315 72 428 311 191 662  37 225 228 886  377 86 205 024 
 
                                                                                                                                                              
14 The resulting ICER-values refer to exact calculations  
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As stated by table 17 and 18, the RMC data set reveals an additional cost to the 
Southern Health Care Region of SEK 13 776 713 for the 62 additional live births as a 
result from implementing the Medical Screening Program, i.e. SEK 222 205 per live 
birth15. The corresponding numbers using the Q-IVF data set are a cost increase of 
SEK 14 663 166, 48 additional live births and a cost increase of SEK 305 483 per live 
birth16. Out of the total costs of implementing the Medical Screening Program, the 
medical screening of females aged 35-42 correspond to SEK 8 602 892 in both data 
sets (not shown in tables).  
 
Table 18. Costs to the Southern Health Care Region using the Q-IVF data set 
Female 
age 
Strict age limit (<39) MS program 
Per live birth Expected 
live 
births 
Cumulative 
cost 
Per live birth Expected 
live 
births 
Cumulative 
cost Hospital 
costs 
Pharmaceuticals Total 
Hospital 
costs 
Pharmaceuticals Total 
<35 138 277 20 918 159 195 304 48 435 180 138 277 20 918 159 195 304 48 435 180 
35 167 227 35 878 203 105 27 5 429 269 162 156 39 468 201 625 25 4 963 743 
36 154 545 35 751 190 296 29 5 602 001 162 123 40 990 203 113 26 5 321 123 
37 155 547 36 218 191 765 27 5 126 134 162 176 40 990 203 166 24 4 833 074 
38 196 708 46 606 243 314 22 5 354 245 190 890 52 047 242 937 20 4 825 010 
39   
   
  190 933 52 047 242 980 19 4 538 616 
40   
   
  194 681 60 084 254 765 16 4 101 478 
41   
   
  194 704 60 084 254 788 16 3 995 299 
42           374 106 88 223 462 329 8 3 596 473 
Total 145 482 25 344  170 954 409 69 946 829 156 941 30 608 185 160 457 84 609 995 
 
In the base case analysis, the total cost of the Strict Age Limit Program added up to 
SEK 97 105 050 using the RMC data set and 94 743 214 using the Q-IVF, while the 
Medical Screening Program cost summed to SEK 117 063 778 and SEK 115 028 728, 
for the RMC and Q-IVF data sets respectively17. When focusing solely on costs that 
fall on the Southern Health Care Region the same costs are numbers are SEK 
72 428 311 and SEK 69 946 829 under the Strict Age Limit Program and SEK 
86 205 024 and SEK 84 609 995 under the Medical Screening Program, using the 
RMC and Q-IVF data sets respectively. In other words, the costs of the Southern 
Health Care Region correspond to approximately 74%18 of the societal cost of ART-
treatment.  The remaining 26% fall on the patients in the form of lost income and 
transportation costs, and their employers in lost production due to sick leave.  
If we assume that all couples who seek ART-treatment will do so irrespective of what 
program is in use, it is the pure hospital costs that are of interest. This assumption 
states that the demand for ART-treatment is constant irrespective but the allocations 
                                                        
15 86 205 024 - 72 428 311; 377 - 315; (86 205 024 - 72 428 311) / (377-315) 
16 84 609 995 - 69 946 829; 457 - 409; (84 609 995 - 69 946 829) / (457-409) 
17 308 270*315=97 105 050; 310 514*377=117 063 778; 231646*409=94 743 214;  
251704*457=115 028 728 (see tables 15 and 16) 
18 72 428 311/97 105 050=0.746 ; 69 946 829/94 743 214=0.738 ; 86 205 024/117 063 778=0.736 ; 
84 609 995/115 028 728=0.736 
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between private and public clinics will vary between the programs (i.e. couples will 
demand the same level of ART-treatment whether it is reimbursed or not). The 
hospital costs then represent the additional cost that will fall under the subsidy and be 
reimbursed by the region, if the Medical Screening Program is introduced. The pure 
hospital costs equal the additional costs of the Medical Screening Program because 
hormone stimulation drugs fall under the high-cost threshold 19, and is hence ascribed 
the Southern Health Care Region for all ART-treatment patients, irrespective of clinic 
type. Consequently, the only cost for the Southern Health Care Region that can be 
fully controlled through the choice of subsidy program is hospital costs.  
Table 17 and 18 translate into an increase of hospital costs by SEK 10 251 344 and 
SEK 12 219 899 when introducing the Medical Screening Program, for the RMC and 
Q-IVF data respectively20. These results correspond to a cost increase per live birth of 
SEK 165 344 for the RMC data, and SEK 254 581 for the Q-IVF21.  
 
6.3. Sensitivity analysis 
To deal with possible inconsistency in our base case results we have conducted a 
sensitivity analysis by varying the uncertain variables and assumptions; demand for 
ART-treatment, medical screening qualification rate and success rate. These variables 
have significant influence in our evaluation of the new proposal from RMC. We 
applied a variation of +/- 30% to assess the effect on the base case results.  
 
The demand for treatment and the medical screening qualification rate are uncertain 
parameters as they depend on non-observed data; extrapolation and non-Swedish data. 
The success rate for RMC includes uncertainty due to a small number of observations, 
especially in the older age groups, while the national Q-IVF register is inconsistent 
with our target population. The same goes for what types of cycles are included in 
success rate calculations. The Q-IVF includes private reproductive clinics that accept 
a wider range of patients than do publically funded treatment centers and the 
nationwide coverage hides regional variations in treatment supply. These variables are 
included in the first part of the sensitivity analysis, the results of which are shown in 
table 19.  
 
The outcome of the sensitivity analysis varies somewhat between the data sets. While 
the effect on the RMC results is sparse, the Q-IVF results show large variation around 
the base case results.  
 
When applying the RMC data set the sensitivity analysis show expected results. 
Varying the demand for treatment downwards is in favor of the Medical Screening 
                                                        
19 The high-cost threshold refers to the system where a medicine is subsidized, and the state pays a 
portion of the costs.  
20 (191 662*377)-(196 842*315)=10 251 344;  (156941*457)-(145 482*409)=12 219 899 
21 10 251 344/62=165 344; 12 219 899/48=254 581 
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Program and brings a dominant ICER of -203 (found in Q4 in the ICER plane in 
figure 1) while an upward variation show very little affect (ICER 72). This is not 
surprising as a lower demand means fewer disqualified patients and thus fewer 
unsatisfactory hormone stimulations to fund. Varying the qualification rate, however, 
show the opposite results and are more in favor of Medical Screening Program with 
an upward variation of 30%. This implies that a more generous qualification rate 
would benefit the Medical Screening Program, which in turn speaks in favor of the 
older patient population. Additionally a decrease in success rate generates a poorer 
result while an increase has the opposite effect, both of which are expected. In sum 
higher success rates, lower treatment demand combined with a more generous age 
limit improves the objective of the Medical Screening Program. The results on the 
ICER-value vary from -203 to 541 and are still fairly small.  
 
Table 19. Sensitivity analysis 
Data Variables -30 % Base case +30 % 
DEMAND, NUMBER OF PATIENTS  
RMC C1 304 143 310 514 315 629 
 
E1 335 377 418 
 
C2 308 270 308 270 308 270 
 
E2 315 315 315 
 
ICER - 203 36 72 
     
Q-IVF C1 244 082 251 704 257 938 
 
E1 411 457 503 
 
C2 231 646 231 646 231 646 
 
E2 409 409 409 
 
ICER 6 259 420 281 
     
MS QUALIFICTION RATE  
RMC C1 319 267 310 514 306 257 
 
E1 335 377 403 
 
C2 308 270 308 270 308 270 
 
E2 315 315 315 
 
ICER 541 36 -23 
     
Q-IVF C1 256 420 251 704 249 822 
 
E1 411 457 486 
 
C2 231 646 231 646 231 646 
 
E2 409 409 409 
 
ICER 12 470 420 236 
     
SUCCESS RATE  
RMC C1 343 496 310 514 286 062 
 
E1 340 377 409 
 
C2 308 270 308 270 308 270 
 
E2 315 315 315 
 
ICER 1388 36 -237 
     
Q-IVF C1 275 418 251 704 234 118 
 
E1 418 457 491 
 
C2 231 646 231 646 231 646 
 
E2 409 409 409 
  ICER 5177 420 30 
Note that only variables for woman aged 35-43 is varied in this sensitivity analysis 
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Considering the Q-IVF data set, however, the variations in the sensitivity analysis 
have greater impact on the results. Varying all factors (demand, qualification rate and 
success rate) upwards move the results in favor of the Medical Screening Program as 
it decreases the ICER value. A downward regulation of the same has the opposite 
effect. The results of varying the demand differ somewhat from those of the RMC 
sensitivity analysis, but this is expected. Even though a decreased demand implies 
fewer unsatisfactory medical screenings greater results, as previously argued, that 
mainly affects the cost structure of the treatment, which is not the only factor in an 
ICER. For the Q-IVF data set the effect side of the analysis seem to be more effected, 
which is expected as it has higher live birth rates initially, while the effects of demand 
on the cost side is more affected for the RMC data that also show the higher cost 
structure of the two. The sensitivity analysis regarding qualification rate have higher 
effects on the Q-IVF data but they move in the same direction as for the RMC and, 
again, the effect the success ratevariation is self-explanatory.  
 
Still, the ICER for the Q-IVF data shows a higher variation around the base case 
outcome (SEK 30 – 12 470 and SEK -237 – 1 388 respectively). However, it is 
noteworthy that when new treatments, with improved treatment effect, are 
implemented with an ICER below SEK 100 000 it is viewed as a low cost per QALY 
or a life year (Socialstyrelsen, 2008). One might argue that a live birth cannot be 
valued in QALY-terms or life years gained, but the ICER of a live birth, using Q-IVF 
data set, are still comparatively low.  
 
It is also important to note that varying the medical screening qualification rate 
upward by 30% it implies that all patients in all age groups will qualify, which is 
highly unlikely and makes the proposed program redundant.   
 
Table 20. Sensitivity analysis using RMC data excluding thawed cycles 
Female 
age 
Treatment demand 
(couples) a 
Incremental success 
rate 
Expected live births Cost per live birth 
Unrestricted 
demand 
Qualified 
in MS 
program 
Strict age 
limit 
(<39) 
MS 
program b 
Strict age 
limit 
(<39) 
MS 
program b 
Strict age 
limit 
(<39) 
MS program 
b 
<35 509 509 0,47 0,47 239 239 280 739 280 739 
35 53 47 0,45 0,59 24 28 309 934 242 775 
36 58 50 0,33 0,46 19 23 404 326 304 943 
37 53 45 0,30 0,40 16 18 455 846 359 368 
38 56 48 0,31 0,41 17 20 445 432 346 804 
39 53 45 - 0,43 - 19 - 317 394 
40 51 40 - 0,41 - 16 - 347 513 
41 50 39 - 0,41 - 16 - 347 513 
42 49 37 - 0,17 - 6 - 831 690 
Total 931 860 0,43 c 0,45 c 315 386 308 270 303 024 
a Demand was observed at RMC in the time period Jan 2011- June 2012 for female patients aged <39, for 39-42 the presented 
demand is extrapolated. To attain the yearly ART-treatment demand for SHCR the observed demand was divided by 1,5. 
b As the RMC’s supply of treatment is age-restricted to females <39 the RMC data set only contained reliable success rates for 
the females up to 38 years of age. The success rates for females 39-42 are extracted from Q-IVF.  
c Total success rates refer to a weighted population average.  
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In the tables 20 and 21, the type of cycles included when estimating the success rates 
for the Medical Screening Program are varied. In the base case fresh cycles that 
reached egg aspiration as well as all thawed cycles were included. It is thereby 
assumed that all thawed cycles are given to patients who would qualify for treatment 
in the Medical Screening Program. This assumption states that none of the patients 
disqualified in the screening process would later end up in the thawed-cycle data and 
thus not affect its success rate. However, there is no indication in the data stating 
whether the ratio of patients in the thawed cycle data would qualify in the Medical 
Screening Program. Therefore, the alternative assumption would be to exclude all 
thawed cycles when estimating the age-dependent success rate. Both assumptions are 
extremes, and draw the result in opposite directions, with the base case inclusion 
being the more restrictive one. Thus the effect of which assumption is used in the 
analysis is of interest. 
 
Table 21. Sensitivity analysis using Q-IVF data excluding thawed cycles 
Female 
age 
Treatment demand 
(couples) a 
Incremental 
success rate 
Expected live births Cost per live birth 
Unrestricted 
demand 
Qualified 
in MS 
program 
Strict age 
limit (<39) 
MS 
progra
m 
Strict age 
limit 
(<39) 
MS 
program 
Strict age 
limit 
(<39) 
MS 
program 
<35 509 509 0,60 0,60 304 304 217 368 217 368 
35 53 47 0,51 0,54 27 25 261 166 253 078 
36 58 50 0,51 0,54 29 27 256 216 255 969 
37 53 45 0,51 0,54 27 25 258 178 255 969 
38 56 48 0,39 0,43 22 21 328 111 317 634 
39 53 45 - 0,43 - 19 - 317 634 
40 51 40 - 0,41 - 16 - 347 448 
41 50 39 - 0,41 - 16 - 347 448 
42 49 37 - 0,17 - 6 - 835 595 
Total 931 860 0,56 b 0,53 b 409 460 231 646 250 013 
a Demand was observed at RMC in the time period Jan 2011- June 2012 for female patients aged <39, for 39-42 the presented 
demand is extrapolated. To attain the yearly ART-treatment demand for SHCR the observed demand was divided by 1,5. 
b Total success rates refer to a weighted population average.  
 
Tables 20 and 21 present the full effects of excluding thawed ART-cycles in the 
success rate estimation but the concluding effect is better explained by the ICER- 
values presented below. Remember that the ICERs were 36 and 420 in the base case 
for the RMC and Q-IVF data set respectively.  
 
𝐼𝐶𝐸𝑅𝑅𝑀𝐶 =  
303 024 − 308 270
386 − 315
= −74 
𝐼𝐶𝐸𝑅𝑄−𝐼𝑉𝐹 =  
250 013 − 231 646
460 − 409
= 360 
 
The RMC data generates a negative ICER-value when excluding thawed cycles from 
the success rate estimate and the Medical Screening Program is thus, by definition, a 
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dominant alternative (found in Q4 in the ICER plane in figure 1). Excluding thawed 
cycles from the success rate decrease the ICER-value for the Q-IVF as well, but the 
value remains positive but decreases to 360. Although excluding thawed cycles 
undeniably benefits the Medical Screening Program, the success rates hold similar 
levels and the ICER-effect is arguably marginal.  
 
In sum, the sensitivity analysis moves the results in expected directions and the 
overall effect seems negligible. Since the Medical Screening Program is often more 
expensive while it always results in more live births than the Strict Age Limit 
Program the result remain open to interpretation for both data sets. However, the 
RMC data set show more promising results in regards of the Medical Screening 
Program than the Q-IVF data, and that the results are even dominant at times.  
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7. DISCUSSION 
ART-treatment is already publically supplied and the question is thus not whether to 
supply treatment but rather to whom it should be supplied. The age limit for the 
proposed Medical Screening Program was set in agreement with clinical experts at 
RMC22. The age limit was set at <43 as it is equivalent to the highest age limits in the 
nation today (Barnlängtan, 2011), and because it is rare for patients >42 to receive 
treatment even at private clinics. The age limit is further supported by previous 
research stating that reproduction is possible for females well over 40 if they have the 
right biological qualities (Broekmans et al, 2004; Haebe et al., 2002). The objective of 
the proposed treatment regimen was to deter from the age fixation and rather focus on 
medical suitability, hence it is preferable to keep the age limit generous to better 
isolate the effect on cost-effectiveness of the medical screening from that of the 
chosen age limit.  
As shown in the results, 42-year-olds have a significantly lower success rate than 
younger women. These lagging success rate brings about vast cost differences per live 
birth for 42-year-olds compared to all other age groups included in our analysis. One 
reason for the low success rates is that they are retrieved from Q-IVF, where the 
success rates are presented in age groups and where the oldest group includes all 42+ 
women (Q-IVF, 2013). Even though the >42 women included in the age group 
probably have a negative effect on the success rate of 42-year-olds, the Q-IVF is the 
only available source of Swedish data for this age category and there is thus no 
reliable alternative. Nevertheless, international studies have shown higher comparable 
cumulative success rates for 42-year-olds (Witsenburg et al., 2005), indicating that the 
cost per live birth may be overestimated in our results.  
Both data sets show promising results for the Medical Screening Program, especially 
considering its effects on the number of live births, but incorporate different absolute 
numbers. The cost per live birth with the Strict Age Limit Program is 33% higher 
based on the RMC data compared to the Q-IVF (SEK 308 000 / SEK 232 000), and 
show significantly fewer expected live births in the target population of the Southern 
Health Care Region (315 compared to 409). When introducing the Medical Screening 
Program the corresponding numbers are a 23% higher cost per live birth with the 
RMC data (SEK 311 000 / SEK 252 000), and 80 fewer live births (377-457). These 
substantial differences bring about the question of what results to focus on. The RMC 
data set deals with the specific target population of the thesis. Furthermore, the more 
costly ART-treatment, with the RMC data, make those results more conservative, and 
underestimation of social costs per live birth are thus less likely. Therefore, the RMC 
results are most trustworthy, at least when considering the Southern Health Care 
Region. Nationwide interpretation, however, should rather be based on the Q-IVF 
data as it includes its target population. In other words, what result is more important 
depends on the chosen perspective. 
                                                        
22 Personal correspondence with Aleksander Giwercman and Margareta Kitlinski 
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Even though introducing the Medical Screening Program show promising 
implications, the most cost-effective treatment program would be to combine a 
medical screening with the current age limit. It would reduce costs for medical 
screenings leading to disqualification, as fewer individuals would be screened 
compared to the Medical Screening Program. It would also raise the success rate per 
treatment compared to the current program, as the unsuitable treatment candidates 
would be disqualified. The number of live births, however, would either decrease or 
remain constant depending on if all patients with potential to achieve live birth would 
qualify for treatment in the screening process. Combined it would result in a lower 
ICER and further reduce the cost per live birth.  
Nonetheless, introducing the Medical Screening Program for the suggested age group 
show relatively low variation in the ICER-values. This is the result of the decreased 
cost in the age group 35-38 as some patients are disqualified from treatment being met 
by the cost increase from allowing treatment for medically suitable women aged 39-
42. In a sense, the Medical Screening Program holds the ICER-value constant while 
increasing live births. The purpose of implementing the Medical Screening Program is 
to allocate health care resources towards patients where it has the greatest effect. 
Treating more patients independent of age and reallocate resources to improve 
probability to reproduce will reduce the relative cost of a live birth even though the 
absolute costs might rise.  
As this thesis compares different allocations of ART-treatment with the common 
target outcome being live births, the CEA methodology is a natural choice. Previous 
studies have pointed out that infertility/childlessness can have significant effect on 
quality of life and that HRQoL measures therefore could be beneficial to evaluate. For 
example, one can argue that a child will contribute to an increased number of societal 
QALYs (Svensson et al., 2008), or that miscarriages can lead to reduced mental health 
for the prospective parents (van Balen et al., 2008; Hujit et al., 2011). Further, a resent 
Danish study suggests that involuntarily childless couples suffer a greater risk of 
dying in early age (Agerbo et al., 2012). However, this thesis evaluates a proposed 
change in ART-treatment and despite the side effects of infertility its main goal is to 
treat childlessness. The exclusion of HRQoL estimates is therefore legitimate, as 
implementing the Medical Screening Program will evidently increase the number of 
live births, implying a decrease in negative side effects of infertility. Therefore an 
inclusion of HRQoL measures would be redundant in this study.   
We have also avoided any monetary evaluations of live births. Partly due to the 
hardship in evaluating a life in monetary terms and partly as the value of a live birth, 
in the perspective of this thesis, refers to the benefit of the child’s parents. It is clear, 
however, that a child born also has a value to the welfare state, for example due to the 
effect on taxation revenues. At the same time there is a risk with conducting 
willingness-to-pay (WTP) studies or time-trade-off (TTO) studies among couples that 
receive ART-treatment as they might over-value a child compared to the overall 
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population. When considering a live birth to primarily be the cure of infertility, such 
monetary valuations are redundant.   
What is of utter importance, however, is the economic burden on couples treated for 
infertility. According to the WHO 16,96% 23  of total health care expenditures in 
Sweden were paid out-of-pocket in 2011 (WHO statistics, 2013), but a majority of 
fertility treatments are performed at private clinics (Socialstyrelsen, 2013) and 32% of 
costs are funded through out-of-pocket payment (Svensson et al., 2008). In other 
words, almost twice as much of the total expenses for fertility treatment are paid out-
of-pocket compared to overall health care. Since infertility is defined as a disease by 
the WHO (WHO, 2013), and treated as such in the Swedish system, the high 
economic burden on fertility patients is hard to legitimize. With the Medical 
Screening Program, more couples would receive subsidized treatment and the 
divergence from the general ratio of publically funded treatment would decrease.  
The disproportionate private funding of treatment implies an excess demand for ART. 
This conclusion is further supported by the interest organization Barnlängtan (Child 
Longing) that primarily works to induce more generous national treatment guidelines. 
The fact that there are private treatment alternatives for couples with monetary 
resources causes political problems. The universal health care system in Sweden was 
designed to provide equal health care to all (Diskrimineringsombudsmannen, 2012; 
SFS 2010:243). However, ART-treatment is expensive and not all couples denied 
subsidized treatment could find private financing. International studies have shown 
that income rates affect the utilization of ART (Ordovensky Staniee et al., 2007; 
Connolly et al., 2010) and that more treatments are pursued when financial aid is 
provided (Connolly et al., 2010). Consequently, the current access to fertility 
treatment depends on socioeconomic status, which calls for improvement of the 
current system.  
Furthermore, the unmet demand for ART-treatment creates a market for private actors. 
Our societal perspective leads us to the question whether private or public health care 
supplies the most cost-effective treatment, regardless of who pays the bill. An 
international meta-analysis concluded that public health care providers are on average 
more cost-effective, primarily due to economics of scale such as regional procurement 
(Dahlgren, 2010; Hollingsworth, 2008). On the same note an Australian study showed 
that private clinics lacked in cost-effectiveness in small clinics while the relationship 
was reversed for large entities (Austrailian government, 2009).  Reproductive clinics 
are generally fairly small, thus private clinics are likely to be less cost-effective 
compared to public clinics. This support an implementation of the Medical Screening 
Program as the new treatment regimen would reallocate couples from private to 
                                                        
23 Private expenditure on health represented 19.1% of total expenditure on health in 2011, out of which 
88.8% were out-of-pocket expenditures. Thus, 16,96% (19,1*0,888=16,96) of total expenditure on 
health was paid out of pocket.  
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public clinics. Although, the mere existence of competition to the public monopolistic 
market can be assumed to increase cost-effectiveness, which speaks against the 
Medical Screening Program based on the same reallocation argument (Svenskt 
Näringsliv, 2010). But it is unreasonable to expect the Medical Screening Program to 
eliminate all demand for private reproductive clinics. For example, couples that 
already have a mutual child will still be denied publically funded treatment. Thus we 
conclude that public clinics are preferable in a societal perspective, which further 
supports the introduction of the Medical Screening Program. 
Although ART-treatment can be of great help for infertile couples, both positive and 
negative side effects have been found. When evaluating the effects of the 
development of ART-treatment on fertility Rainer et al. (2011) found that 
improvements in ART have a directly positive effect on fertility rates. However, they 
also found that the increased fertility rates could cause indirect changes in behavior, 
potentially counteracting the positive ART-effects. Such behavioral changes include 
women who would otherwise have tried to have children to postpone childbirth to 
later in life when the success rate of conceiving is lower, despite ART-treatments 
(Rainer et al, 2011). National statistics show that the average age of both women and 
men having their first child has increased rapidly in Sweden during the last 40 years 
(Statistics Sweden, 2012:I). If ART is reliable alternative it may induce this trend as it 
supplies a type of reproductive insurance. It is important to remember, however, that 
although ART-treatments constantly improve and show good success rates, there is no 
guarantee of a successful outcome. It is still a fact that the success rate of ART-
treatments, as well as natural fertility, decline with age. This argumentation speaks 
against implementing the Medical Screening Program.  
An additional aspect of the increase in parental age is the changing societal structures. 
Instead of the family being the center of most female lives, education and careers 
have become increasingly important. Today, more than half the student population at 
university level is female (Högskoleverket, 2012). Simultaneously, the norm of what 
is expected of a young woman in terms of reproduction also shifts. We consider it 
likely to be the norm shift that has the larger influence on the average maternal age at 
first births than the availability of ART. However, one cannot deny that a too 
extensive safety net may induce a behavior that, counterproductively, increases the 
problem of infertility and thus the demand for treatment by more couples waiting to 
reproduce late in life (Rainer et al., 2011). One solution could be to promote a wider 
knowledge of the age-dependence of fertility to deter young people from waiting to 
long to reproduce (Mac Dougall et al, 2013). If the age-dependence of fertility was 
more acknowledged individuals might make more favorable decisions regarding 
reproduction and, if so, treatment would be allocated towards those of non self-
induced needs.  
Previous studies have also suggested a positive correlation between maternal 
education and ART-treatments utilization. The results show that ART treatments 
increase along with educational level (Socialstyrelsen, 2013). Additionally, Lundberg 
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et al (2012) has shown a positive relationship between children’s skills and health 
status and maternal education. These results combined imply a higher value of a child 
conceived through ART than for an average child. Therefore it is not unreasonable to 
assume a high societal WTP for ART-treatments due to women seeking treatment 
being disproportionally well educated. At the same time this finding implies that our 
use of average wage rates to estimate production loss for the women receiving ART-
treatment, and their spouses, are underestimated resulting in too low treatment cost 
results. However, there is no socioeconomic data included in any of the data sets and 
any conclusion on the subject therefore requires further investigations.   
Moreover, it is of vital importance for western countries to find paths to promote 
reproduction (Conolly et al., 2010). The current demographic trend of the developed 
world should welcome any boost to fertility rates (Statistics Sweden, 2012:I). The 
negative economic consequences for countries with low levels of reproduction are 
evident and there is a great need for any investment that increases, or even stabilizes, 
fertility rates (Rainer et al., 2011; Ds 2013:8).  
Presently, over 3% of children born in Sweden are the product of ART, a number that 
is likely to increase if the trend continues. Thereby, ART-treatment may contribute 
with a considerable number of future taxpayers with spillover effects for generations 
to come (Conolly et al., 2010). Preserving an adequate number of taxpayers in relation 
to the total population is an ongoing struggle in developed countries, not the least in 
order to solve impending pensions system difficulties (Ds 2013:8). To that 
background Svensson et al. (2008) evaluated the effects of ART-treatment on the 
Swedish nation. The net present value (NPV) of an IVF-child was estimating by the 
prognostic economic interaction between the child and the Swedish government over 
a lifetime. The study estimated a positive NPV for IVF-treatment and assessed a 
break-even point at age 41 (Svensson et al., 2008). Thus making public funding of 
fertility treatment a sound investment if the child lives at least 41 years, making the 
profitability of ART undeniable in this perspective.  
Even though this thesis argues that ART-treatment should be promoted it is 
noteworthy that there are other available solutions to childlessness, such as adoption, 
surrogacy and foster care. However, surrogacy is not yet legal in Sweden forcing 
couples to seek such treatment abroad, which in turn complicates monitoring health 
care quality and the potential exploration of the surrogate mother (SMER, 2013). 
Adoption is available through Swedish agencies, but getting approved involves an 
extensive and exhausting process. According to Swedish guidelines the recommended 
maximum age is 42 years old for both parents (SOSFS 2008:8), which further 
validating the age limit of the Medical Screening Program as both solutions results in 
prospective parenthood. Today the cost of adopting is completely born by the 
prospective parents, causing a negative incentive to adopt compared to pursuing 
subsidized ART-treatment. Foster care is a risky solution to childlessness as the 
child’s biological parents retain legal rights to the child if they can prove themselves 
able. However, foster parents receive governmental aid to care for the child, which 
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causes a different structure of incentives than ART-treatment and adoption. 
Regardless, the most important difference between ART-treatment and adoption or 
foster parenting is that they do not result in a biological child. Therefore, and because 
surrogacy is still illegal in Sweden, there are no perfect substitutes to ART-treatment 
to reproductively challenged couples even though the suggested alternatives in fact 
cures childlessness. 
Finally, the recent report from the Swedish National Council on Medical Ethics 
proposed an introduction of a medical assessment as the basis of qualification for 
ART-treatment, and argued its ethical superiority to a fixed age limit (SMER, 2013). 
However, the Swedish National Council on Medical Ethics refrained to present details 
regarding how the medical assessment should be constructed. The Medical Screening 
Program brought to light in this thesis was partly inspired by the Swedish National 
Council on Medical Ethics report. Thus, one of the objectives of this thesis was to 
complement the Swedish National Council on Medical Ethics report and draw the 
attention of decision makers to the inadequacy of the current ART-treatment program.   
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8. CONCLUSION 
Introducing the Medical Screening Program results in more performed treatments, 
higher success rate and more live births relative to the current Strict Age Limit 
Program. At the same time the proposed program would increase the cost per live 
birth. However, the cost increase with the Medical Screening Program may be 
motivated as Medical Screening Program generates more live births and the monetary 
differences per live birth are fairly small. What is clear, however, is that the Medical 
Screening Program will generate a higher total cost of publically funded ART-
treatments.  
 
The majority, around three fourths, of the societal cost of publically funded ART-
treatment is paid by the universal health care system (i.e. the county council) while 
the remaining fourth fall on the patients and their employers. 
 
There are some indications that increased availability of publically funded ART-
treatment induces counterproductive behavior. However, the greater effect on when in 
life people chooses to reproduce is likely related to shifting social norms. It is 
essential for western countries to promote fertility rate, due to the economic 
implications of an aging population.  
 
In sum, the proposed Medical Screening Program show promising potential for cost-
effectiveness from a societal perspective.  
 
9. FURTHER RESEARCH 
The largest shortcoming of this thesis is the lack of a reliable data set that covers the 
target region and includes all relevant age groups. A longer monitoring period, where 
patients were followed from their first visit to the end of all available treatment cycles, 
would also be preferable. Moreover, the optimal data set would reveal follicle count 
prior to egg aspiration so that qualification rates could be determined. The limited 
data sets used in this thesis thus calls for further research within the area, in order to 
retrieve results closer to the real outcomes of implementing the Medical Screening 
Program.  
If a program shift is executed, close monitoring is of essence for future reliable 
evaluation. If the program shift shows suboptimal results, evaluations of additional 
program propositions should be conducted.  
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11. APPENDIX 
11.1. Age restriction of ART 
Table 22. Age restrictions per county council 
 County Council Evaluation  IVF Egg donation 
Women Men Women Men Women Men 
Skåne     39 55 39 55 
Blekinge     39 55 39 55 
Kronoberg 43 55 39 55 39 55 
Halland a             
Götaland a             
Jönköping             
Kalmar     38 55 38 55 
Stockholm 40 56 40 56 40 56 
Gotland 41 55 40 55 40 55 
Gävleborg     38 55 38 55 
Dalarna 40 55 40 55 40 55 
Sörmland 38 55 38 55 38 55 
Östergötland 41 54 38 55 38 55 
Värmland 43 55 40 55 40 55 
Uppsala 40 55 40 55 40 55 
Örebro 42 55 40 55 40 55 
Västmanland 40 55 40 55 40 55 
Uppsala 40 55 40 55 40 55 
Norrbotten 40 56 37 55 37 55 
Jämtland 40   37 55 37 55 
Västerbotten 23-37 23-54 24-37 24-55 24-37 24-44 
Västernorrland a             
Source: Barnlängtan (Child Longing) interest organization.  
a Information about these county councils is absent because they are divided between different Health Care Regions. For example, 
the north part of Halland goes under the Western Region while the southern parts belong to the South Region.  
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11.2. Treatment schedule 
 Figure 2. ART-treatment cycle 
Source: Griffiths et al. 2010 (A CEA of IVF by maternal age and number of treatment attempts 
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11.3. Cost calculations  
Table 23. initial blood work 
Type of test Cost Unit Reference 
FSH 30 per test SHCR pricelist 
LH 30 per test SHCR pricelist 
TSH 21 per test SHCR pricelist 
Infectious sample (HTLV) a 216 per test SHCR pricelist 
Rubella 97 per test SHCR pricelist 
Infectious sample b 216 per test SHCR pricelist 
Total 610 per patient  
a Only for female patients 
b Only for male patients 
Table 24. Pharmaceuticals 
Drug 
therapy 
Active 
substance 
Pharmace
utical 
Type 
Concen-
tration 
Unit 
Packa
ge size 
(numb
er of 
units) 
Packag
e price 
Price 
per unit 
Weighted 
use, 
portion of 
patients 
Avera
ge 
dose 
(if in 
use) 
Avera
ge 
treat
ment 
days 
Treatm
ent cost 
Down 
regulation 
Nafarelin Synarela Nasal spray 200 μg/dose  Dose 60 1134,5 18,91 1 60   1134,5 
Hormone 
stimulatio
na 
              2,83 1 
Age-
dep. b 
11,7   
  
Follitropin 
alfa 
Gonal-f c 
Injection 
fluid 
900 IE / 
1,5ml 
IE 900 2662 2,96 0,25   11,7   
  
Follitropin 
beta 
Puregon 
Injection 
fluid 
900 IE / 
1,08ml 
IE 900 2662 2,96 0,25   11,7   
  Menotropin Menopur 
Powder 
and 
injection 
fluid 
1200 IE IE 1200 3534 2,95 0,25   11,7   
  
Urofollitropi
n 
Fastimon 
Powder 
and 
injection 
fluid 
150 IE IE 1500 3673 2,45 0,25   11,7   
Antagonist Ganirelix Oraglutran 
Injection 
fluid 
0,25 
mg/0,5 ml 
mg 5 1521 304,20 1 6,5   1977,3 
Ovulation 
trigger 
Koriongonatr
opin alfa 
Ovitrelle 
Injection 
pen 
250 μg μg 1 342     1 1 342 
At egg 
aspiration 
                1     26 
  Paracetamol Panodil Tablet 1g 
table
t 
50 134 2,68 1 1   3 
  Meklozin Postafen Tablet 25mg 
table
t 
100 85,5 0,855 1 1   1 
  Fentanyl 
Fentanyl 
B. Braun 
Ampoule 50 μg /ml ml 100 209 2,09 1 1,25   3 
  Midazolam 
Midazola
m Actavis 
Ampoule 1 mg/ml ml 50 141 2,82 1 0,75   2 
  Propofol 
Propofol-
®Lipuro 
Injection 
fluid 
10 mg/ml ml 1000 1526 1,526 0,1 1,5   0 
  Mevipakain 
Carbocain
® 
Injection 
fluid 
10mg/ml ml 100 171 1,71 1 10   17 
Follow-up 
treatment 
Progesteron Crinone® 
Vaginal 
gel 
8% dose 15 506 33,73 1       
 Fresh  
cycles 
              
 
  1 15 506 
 Stimulated 
thawed 
cycles 
              
 
  2 13 877 
 Additional 
stim. 
thawed 
cycles if 
clin.preg.  
              
 
  2 49 2429 
a The hormone stimulation drugs are assumes to be used in 25% of patients each, thus an average of SEK 2,83/IE was used  in the 
treatment cost calculations 
b See table 25 below  
c New market price from October 1st 2013 according to TLV decision. 
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Table 25. Hormone stimulation 
Age Portion 
of 
patients 
Dose (E/day) Weighted 
dose 
Cost per 
dose 
Average 
treatment days 
Treatment cost 
          LP a SP a LP a SP a Weighted 
<35 0,66     2,83 12,5 10,5 4641 3898 4344 
     <31 0,33 112,5 37 2,83 12,5 10,5       
     31-
35 
0,33 150 50 2,83 12,5 10,5       
>35 0,34 225 76 2,83 12,5 10,5 7952 6680 7443 
Total 1   163 2,83 12,5 10,5       
a LP stands for long protocol and represents 60% of the patients irrespective of age, while SP stands for short protocol and respresents 
the remaining 40% of patients. 
 
Table 26. Consumer Price Index (CPI) 
Year CPI              
(yearly average) 
CPI conversion 
into 2013 (SEK) 
2000 260,7 1,203 
2001 267,1 1,175 
2002 272,8 1,150 
2003 278,1 1,128 
2004 279,2 1,124 
2005 280,4 1,119 
2006 284,22 1,104 
2007 290,51 1,080 
2008 300,61 1,044 
2009 299,66 1,047 
2010 303,46 1,034 
2011 311,43 1,007 
2012 314,2 0,998 
2013* 313,722 1,000 
*Average of the published CPI-indicatorscovering Jan-May 2013 
Source:http://www.scb.se/Pages/TableAndChart____272151.aspx 
 
Table 27. Average wage rates 
  Monthly wage 
2012 
CPI conversion from 2012 
to 2013 
Monthly wage 2013 Work hours per 
month 
Hourly wage, 
2013 
Men 32100 1,0015 32051 160 200 
Women 27600 1,0015 27558 160 172 
All 29800 1,0015 29755 160 186 
Source: Wages were retrieved from Medlingsinstitutet (www.mi.se/lonestatistik/) and CPI information were retrieved from Statistics 
Sweden (http://www.scb.se/Pages/Product____33783.aspx) 
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Table 28. Social benefits 
Benefit 
  
Percentage of wage 
Workers Officials Average* 
Statutory payroll tax 31,42 31,42 31,42 
Pension and insurance payments in 
agreement with labor unions 
5,2 15 10,1 
Total 36,62 46,42 41,52 
*a 50/50 division between workers and officials is assumed  
Source: All benefit information was retrieved from  the statistics collector Ekonomifakta (www.ekonomifakta.se) 
 
Table 29. Hourly production loss 
  Hourly wage  Employee 
benefits (%) 
Total hourly 
production loss 
Men 200 41,52 283 
Women 172 41,52 244 
All 186 41,52 263 
 
Table 30. Population and distances in SHCR 
County Population Population weight Largest city Distance from largest 
town to RMC (km) a 
Weighted 
distance (km) 
Halland b 168 064 0,10 Halmstad 140 13 
Kronoberg 185 695 0,11 Växjö 243 26 
Blekinge 152 452 0,09 Karlskrona 207 18 
Skåne 1 262 028 0,71 Helsingborg c 66,7 48 
Total 1 768 239 1,00     57 
a The distance from the largest town is used as a proxy for the average distance in the county 
b Only the municipalities that belong to the Southern Health Care Region is included in the population 
c Helsingborg is the second largest town in Skåne. Helsingborg is used because RMC is located in Malmö and an average distance for 
the whole Skåne population of zero kilometers would largely underestimate the true average distance in the county. 
Source: Population information was retrieved from the Swedish Association of Local Authorities and Regions (www.skl.se). The 
distances from each region's largest city was retrieved from Google Maps (www.maps.google.com).  
 
Table 31. Transportation costs 
Weighted distance 57 
Cost, SEK/km a 1,85 
Transportation cost, one way 105 
Transportation cost, per visit 210 
a Amount reimbursed per km by the Swedish Tax Agency (www.skatteverket.se) 
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11.4. Example of treatment cost calculation  
Table 32. Treatment cost calculations, <35, cycle 1, long protocol 
Treatment 
step 
Visi
t no 
Visit 
Entity 
(RMC/PC
/home) 
Detailes and comments Unit 
cost 
Indirect costs Treat. 
cost 
Prev. Total 
cost 
per 
cycle 
Transp. 
cost 
Hour
s off 
work 
Prod. 
loss 
Physician 
visit 
1 RMC Examination including ultrasound and 
blood tests (F) 
3134 210 6 1579 4923 1 4923 
           FSH 30       30 1 30 
           LH 30       30 1 30 
           TSH 21       21 1 21 
           Infectious samples (HTLV, F) 216       216 1 216 
           Rubella 97       97 1 97 
      Andrological exam including blood test 
and (M) 
4740       4740 1 4740 
           Infectious samples (M) 216       216 1 216 
  2        Sperm samples  1438 210 5 1316 2964 2 5928 
           Sperm analysis 1700       1700 2 3400 
Physician 
visit 
3 RMC Consultation 1714 210 8 2105 4029 1 4029 
Nurse 
visit  
    Consultation and treatment information 1419       1419 1 1419 
Down 
regulation  
  Home Pharmaceutical. Supressing woman's 
normal fertility cycle  
1135       1135 1 1135 
Hormone 
stimulatio
n 
  Home Pharmaceuticals 4641       4641 1 4641 
Nurse 
visit 
4 PC   493   5 1316 1809 1 1809 
      Blood test (F) - estradiol 36       36 1 36 
Doctor 
visit 
5 RMC Ultrasound 1 2180 210 6 1579 3969 1 3969 
Doctor 
visit 
5.2 RMC Ultrasound 2 - only in case of inadequate 
follicle maturity at ultrasound 1 
2180 210 6 1579 3969 0,85 3374 
Doctor 
visit 
5.3 RMC Ultrasound 3 - only in case of inadequate 
follicle maturity at ultrasound 2 
2180 210 6 1579 3969 0,075 298 
Cost of 
Medical 
screening 
                  40310 
    Home Ovulation trigger 342       342 1 342 
Egg 
aspiration 
6 RMC Pharmaceutical use at egg aspiration 26 210 16 4211 4446 0,975 4334 
      Sperm sample 1438       1438 0,975 1402 
           Sperm analysis 1700       1700 0,975 1657 
ICSI or 
IVF 
         IVF 18252       18252 0,404 7380 
           ICSI 23430       23430 0,596 13956 
Embryo 
transfer 
7 RMC     210 6 1579 1789 0,809 1448 
Follow up 
treatment 
  Home Hormone stimulation 506       506 0,809 410 
Nurse 
visit  
8 PC   493   2 526 1019 0,809 825 
      Pregnancy test (hCG blood test) 45       45 0,809 36 
  9 RMC Ultrasound (if clinical pregnancy) 1420 210 6 1579 3209 0,295 946 
Total 
protocol 
cost 
                  73047 
 
 
 
